Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

The burden of disease in Spain: results from the global burden of disease study 2010

  • Josep Maria Haro1, 2Email author,
  • Stefanos Tyrovolas1, 2,
  • Noe Garin1, 2,
  • Cesar Diaz-Torne3,
  • Loreto Carmona4,
  • Lidia Sanchez-Riera5, 6,
  • Fernando Perez-Ruiz7 and
  • Christopher JL Murray8
BMC Medicine201412:236

https://doi.org/10.1186/s12916-014-0236-9

Received: 2 July 2014

Accepted: 12 November 2014

Published: 5 December 2014

Abstract

Background

We herein evaluate the Spanish population’s trends in health burden by comparing results of two Global Burden of Diseases, Injuries, and Risk Factors Studies (the GBD studies) performed 20 years apart.

Methods

Data is part of the GBD study for 1990 and 2010. We present results for mortality, years of life lost (YLLs), years lived with disability, and disability-adjusted life years (DALYs) for the Spanish population. Uncertainty intervals for all measures have been estimated.

Results

Non-communicable diseases accounted for 3,703,400 (95% CI 3,648,270–3,766,720) (91.3%) of 4,057,400 total deaths, in the Spanish population. Cardiovascular and circulatory diseases were the main cause of mortality among non-communicable diseases (34.7% of total deaths), followed by neoplasms (27.1% of total deaths). Neoplasms, cardiovascular and circulatory diseases, and chronic respiratory diseases were the top three leading causes for YLLs. The most important causes of DALYs in 2010 were neoplasms, cardiovascular and circulatory diseases, musculoskeletal disorders, and mental and behavioral disorders.

Conclusions

Mortality and disability in Spain have become even more linked to non-communicable diseases over the last years, following the worldwide trends. Cardiovascular and circulatory diseases, neoplasms, mental and behavioral disorders, and neurological disorders are the leading causes of mortality and disability. Specific focus is needed from health care providers and policy makers to develop health promotion and health education programs directed towards non-communicable disorders.

Keywords

Disability-adjusted life years Global Burden of Diseases, Injuries, and Risk Factors Studies Spain Mortality Years lived with disability Years of life lost

Background

The impact of diseases and injures on population health is usually assessed with measures of mortality and non-fatal health outcomes [1]. These estimates are used to signal the most relevant public health problems, allow comparison between different populations and different health conditions, and assess changes over time. The only comprehensive effort to date to estimate summary measures of the global population health, by cause and by world region, is the ongoing Global Burden of Diseases, Injuries, and Risk Factors (GBD) initiative [2],[3].

The first GBD study analyzed data from 1990 [4] and was published in 1993. Since then, a number of updates have been published [5]. The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) has updated and expanded previous efforts to include 1,160 diseases and injury sequelae from the previous analysis, which included 483 diseases. The most important limitation of previous GBD studies is that results were not estimated with uncertainty [6]. Specifically, uncertainty can come from many sources, including heterogeneity in the empirical data that are available and uncertainty in the indirect estimation models used to make predictions for populations with little or no data. However, this limitation has been solved in the recent analysis of the GBD 2010 study.

The GBD initiative uses disability-adjusted life years (DALYs) and mortality as the summary measurements of the impact of health conditions on population health. The DALY combines the years of life lost (YLLs) due to premature mortality and the years lived with disability (YLDs). The use of DALYs as measure of impact, the inclusion of a large number of communicable and non-communicable conditions, the analysis of the impact of health conditions stratified by gender and age, and the effort to use comparable methodologies across countries and regions make the GBD project an excellent tool to understand the determinants of health and their variability across time and regions. According to previous reported global results, in 1990, 47% of DALYs were attributed to communicable, maternal, neonatal, and nutritional disorders, 43% to non-communicable diseases, and 10% to injuries, while in 2010, this had reversed to 35%, 54%, and 11%, respectively [5]. Besides clear differences among countries with different socioeconomic conditions, heterogeneity is also present when analyzing and comparing countries with more similar socioeconomic conditions. For example, in the United Kingdom (UK), mortality and disability as well as overall health has improved in absolute terms between 1990 and 2010. However, according to Murray et al. [7], the UK performed worse than other EU countries in age-standardized mortality, YLLs, and life expectancy rates. The UK age-standardized DALY rates for chronic obstructive pulmonary disease, disorders of drug use, lower respiratory infections, breast cancers, and preterm birth complications were significantly higher compared to the mean of the EU-15 area countries [7].

Spain is a southern European country with distinct sociodemographic and health characteristics; while in former years large proportions of the population adhered to a Mediterranean diet, dietary habits are changing rapidly with alarming rates of obesity and smoking and alcohol drinking are still highly prevalent in the country despite public health efforts to reduce consumption. Nevertheless, the, until recently, universal coverage of the National Health System also facilitates good health care levels and the implementation of some preventive actions. Until now, to the best of our knowledge, only two studies have tried to assess the burden of disease in Spain. Genova-Maleras et al. [8] estimated the impact of different diseases using DALYs. According to the researchers, the DALYs due to all diseases and injuries were estimated at 5.1 million in Spain. Almost 90% of these were attributed to chronic diseases. Specifically, the leading causes of DALYs were neurological and mental disorders, followed by malignant neoplasms and cardiovascular diseases [8]. However, the aforementioned results were partially limited, since the mortality data came from Spanish registers, while the incidence and severity rates were obtained from estimations of the WHO for a variety of European countries (i.e., WHO European Region Eur-A). A more recent project, but only including data from Valencia, revealed similar results [9], reporting that the number of DALYs gradually increased with age and almost 27% of all DALYs occurred among people over the age of 70 [9].

Given the scarcity of analysis of the data from Spain and the relevance of learning from the experience and comparison with similar and not so similar countries, the aim of the present work was to evaluate the change in burden of disease in Spain, comparing the available data of the GBD over time, between 1990 and 2010.

Methods

Overview

The GBD 2010 study estimates the impact of 291 diseases and injuries and 67 risk factors for 187 countries distributed into 21 world regions between 1990 and 2010. For each cause, 1 to 24 sequelae were defined. Sequelae are the clinical outcomes that can be related to specific diseases and injuries such as neuropathy due to diabetes. In total, the study includes 1,160 sequelae. More detailed information about data and analysis for the GBD 2010 have been previously reported [2],[5],[6],[10],[11]. For the present analysis, only information regarding Spain will be reported.

Measurements

We report data on mortality, YLLs due to premature mortality, YLDs, and DALYs. Age-specific mortality rates for Spain were estimated for each sex. As in other developed countries, information about deaths was predominantly driven by data from official vital registration systems [12]. The denominators were based on Spanish census returns and intercensal estimates. Similarly to the other 187 countries of the GBD study, the estimated number of deaths and YLLs was based on 235 defined underlying causes of mortality from the list of 291 diseases and injuries, for 20 age groups and both sexes [2],[13]. The YLLs were computed by multiplying the number of deaths in each age group by a reference life expectancy [2]. The YLDs were computed by multiplying the prevalence of a sequelae by its disability weight (DW), used to quantify population’s health losses. This procedure varies slightly compared to previous GBD studies, in which incidence and average duration of the case until remission was used instead of prevalence [14]. A total of 1,160 possible sequelae of diseases and injuries were analyzed. Murray et al. [5] have described the systematic analysis of available data conducted for each sequelae with regard to the prevalence, incidence, remission, and excess mortality. For each age-sex-year group, estimates were made for most sequelae using Bayesian meta-regression methods. DWs were obtained for 220 health states covering the 1,160 sequelae [6]. For each sequelae, DWs were derived based on the scoring of short lay descriptions of the relevant health domains in large population-based studies in several countries (i.e., Peru, USA) and through an open internet survey [15]. Finally, for the estimation of the DALYs, the arithmetic sum of YLLs and YLDs was used.

The YLDs age-standardized rates for each cause, in 1990 and 2010, were calculated. For this procedure the WHO age-standard was used as has been described in former GBD analyses [16]. Spain’s YLDs age-standardized rankings were compared with other European countries. The aforementioned comparison of YLDs age-standardized rates provides an opportunity to compare the YLDs across the European countries in specific periods, controlling for number variations and crude rates due to differences in population age.

In order to differentiate the change in DALYs due to demographic variations from those to health changes or other reasons, two counterfactual increases in total DALYs were calculated based on the 1990 population sex and age distribution and compared with the observed increase from 1990 to 2010: i) the expected increase in total DALYs if total population increase had been as observed but without change in the age/sex structure or in strata-specific DALY rates; ii) the expected increase in total DALYs if the population and its age/sex structure had changed as observed but without change in strata-specific DALY rates (application of 1990 stratum-specific DALY rates to the 2010 population strata sizes). The first estimate, (i), provides the increase attributable to population increase without population aging; (ii) minus (i) gives the increase attributable to population aging and the observed increase from 1990 to 2010 minus (ii) gives the increase attributable to changes in stratum-specific DALY rates.

Uncertainty levels

Uncertainty levels for mortality rate were estimated using standard simulation methods [2]. Uncertainty for mortality and YLLs reflected uncertainty in the levels of all-cause mortality and uncertainty in the estimation of each mortality cause, in each age group, sex, and year. Uncertainty in the disability weight for each sequelae was propagated into the estimates of YLDs for each disease and injury. For a more accurate estimation of YLDs, the effect of comorbidity was taken into account, as explained in Vos et al. [10]. Specifically, the procedure of microsimulation for each country (explicitly here for Spain), age, sex, and year were used in a large number of simulated individuals. This standard simulation method was repeated 1,000 times to be able to capture uncertainty in the prevalence of all sequelae and disability weights [10].

Results

From 1990 to 2010, the overall Spanish population increased by almost 15% (from 38,914,907 to 44,558,264 people) (Table 1). A similar increase was observed in males and females, close to 15% and 14%, respectively. The population of older adults in Spain presented the highest increase among all age groups. For example, in octogenarians (aged 80+ years), the increase was almost double. The highest decrease of population was observed in the younger ages (0–20 years old), where the population dropped by 21%.
Table 1

Spanish population (millions) in 1990 and 2010

 

1990

2010

Δ%

Both sexes, all ages

38,914,907

44,558,264

15

  0–19 years old

11,078,521

8,781,618

−21

  20–39 years old

11,618,044

13,004,297

12

  40–59 years old

8,820,927

12,589,546

43

  60–79 years old

6,240,651

7,878,252

26

  80+ years old

1,156,764

2,304,554

99

Males, all ages

19,057,590

21,964,405

15

Females, all ages

19,857,317

22,593,859

14

Table 2 illustrates the main causes of mortality and YLLs by gender and age group for the Spanish population. As expected, non-communicable diseases were the major cause of mortality, accounting for 3,703,400 (95% CI 3,648,270–3,766,720) (91.3%) of 4,057,400 total deaths. Cardiovascular and circulatory diseases were the main cause of mortality among the non-communicable diseases (34.7% of total deaths), followed by neoplasms (27.1% of total deaths). The third category, injuries, accounted for 4.1% of Spanish deaths [170,040, 95% CI (148,350–187,710)].
Table 2

Main causes of mortality and years of life lost (YLLs) by age groups and by gender, for the Spanish population in 2010

Deaths (hundreds)

YLLs (hundreds)

 

Both sexes, all ages

<1 year

1–19 years

20–39 years

40–59 years

60–79 years

80+ years

Males, all ages

Females, all ages

Both sexes, all ages

Males, all ages

Females, all ages

All causes

4,057.4

16.9

14.9

74.9

345.6

1,283.0

2,322.2

2,049.9

2,007.5

54,562.8

32,736.3

21,826.5

Communicable, maternal, neonatal, and nutritional disorders

183.96 (157.53–214.88)

10.4

1.3

5.8

14.3

35.6

116.6

89.84 (74.84–110.39)

94.12 (75.54–117)

3,124.9 (2,873.32 – 3,397.56)

1,818.74 (1,629.9 – 2,038.1)

1,306.17 (1,154.6 – 1,471.72)

HIV/AIDS and tuberculosis

16.76 (14.7–19.39)

0.0

0.0

3.6

7.5

3.0

2.8

12.12 (10.21–14.78)

4.63 (3.85–5.63)

555.31 (480.43–649.07)

420.04 (349.4–512.85)

135.27 (115.48–159.21)

Diarrhea, lower respiratory infections, meningitis, and other common infectious diseases

138.1 (113.55–169.75)

0.4

0.7

1.5

5.2

27.8

102.4

64.36 (49.5–85.36)

73.75 (55.79–96.84)

1,432.97 (1,244.82 – 1,680.97)

783.48 (640.77–986.07)

649.49 (534.56–788.48)

Neglected tropical diseases and malaria

1.66 (0.84–3.19)

0.0

0.0

0.0

0.0

0.3

0.5

0.62 (0.31–1.14)

1.04 (0.4–2.45)

49.34 (27.47–89.06)

20.64 (11.35–36.68)

28.7 (11.85–61.85)

Maternal disorders

0.32 (0.22–0.42)

0.0

0.0

0.0

0.0

0.0

0.0

–*

0.32 (0.22–0.42)

16.2 (10.86–21.52)

–*

16.2 (10.86–21.52)

Neonatal disorders

9.8 (8.54–11.03)

9.8

0.0

0.0

0.0

0.0

0.0

5.5 (4.63–6.4)

4.3 (3.4–5.11)

842.8 (734.44–948.51)

473.06 (398.16–550.48)

369.74 (292.36–439.4)

Nutritional deficiencies

9.52 (5.24–13.19)

0.0

0.0

0.0

0.0

1.3

7.8

3.24 (1.82–4.57)

6.29 (2.72–9.74)

82.92 (48.12–106.53)

35.8 (20.2–45.91)

47.12 (22.07–68.11)

Other communicable, maternal, neonatal, and nutritional disorders

7.79 (5.07–9.57)

0.0

0.0

0.1

1.1

3.1

3.1

4 (2.37–5.02)

3.8 (2.32–5.06)

145.36 (100.68–168.33)

85.71 (56.07–102.53)

59.64 (39.63–73.75)

Non-communicable diseases

3,703.42 (3,648.27 – 3,766.72)

6.1

7.5

39.6

297.0

1.205.7

2.147.2

1,853.9 (1,818.92 – 1,891.49)

1,849.53 (1,807.93 – 1,895.78)

46,970.31 (46,249.68–48,068.86)

27,624.78 (27,059.44 – 28,507.45)

19,345.53 (18,957.63 – 19,922.49)

Neoplasms

1,101.24 (1,014.78 – 1,168.33)

0.0

3.2

16.5

166.4

513.7

401.3

671.72 (603.52–728.99)

429.52 (386.58–469.72)

18,488.09 (17,216.3 – 19,429.35)

11,636.36 (10,542.8 – 12,486.19)

6851.73 (6324.27–7307.47)

 Esophageal cancer

19.45 (14.41–26.46)

0.0

0.0

0.0

4.9

9.9

4.6

16.47 (11.79–23.21)

2.97 (1.89–4.47)

388.59 (286.84–536.01)

349.47 (253.61–493.6)

39.11 (23.43–53.73)

 Stomach cancer

64.9 (49.72–93.74)

0.0

0.0

0.7

7.9

29.2

27.1

36.68 (24.69–52.52)

28.22 (18.13–51.95)

986.61 (741.61 – 1,378.18)

613.71 (403.16–859.83)

372.9 (229.02–636.47)

 Liver cancer

52.14 (42.39–65.26)

0.0

0.0

0.3

6.8

26.6

18.2

32.93 (25.09–42.88)

19.2 (14.55–28.42)

837.17 (701.49 – 1,036.73)

591.1 (470.26–768.21)

246.07 (197.75–342.93)

 Larynx cancer

17.38 (9.03–31.26)

0.0

0.0

0.0

4.8

8.9

3.6

16.56 (8.38–30.24)

0.83 (0.38–1.31)

361.52 (190.52–673.47)

348.38 (180.74–659.95)

13.14 (5.59–22.2)

 Trachea, bronchus, and lung cancers

191.92 (123.09–218.32)

0.0

0.0

1.3

39.2

105.4

46.0

163.47 (99.12–188.56)

28.45 (12.43–35.7)

3,641.21 (2,366.65 – 4,115.82)

3,088.96 (1,923.35 – 3,509.43)

552.25 (221.23–698.17)

 Breast cancer

65.87 (58.98–73.57)

0.0

0.0

2.0

16.6

24.7

22.5

–*

65.87 (58.98–73.57)

1281.35 (1177.3–1410.43)

–*

1,281.35 (1,177.3 – 1,410.43)

 Cervical cancer

9.09 (5.98–13.94)

0.0

0.0

0.4

2.9

3.3

2.4

–*

9.09 (5.98–13.94)

207.1 (130.86–301.52)

–*

207.1 (130.86–301.52)

 Uterine cancer

12.5 (5.29–17.15)

0.0

0.0

0.0

1.2

6.3

5.0

–*

12.5 (5.29–17.15)

181.01 (81.49–256.02)

–*

181.01 (81.49–256.02)

 Prostate cancer

76.48 (43.85–133.33)

0.0

0.0

0.0

1.3

29.5

45.7

76.48 (43.85–133.33)

–*

818.99 (459.29 – 1,372.44)

818.99 (459.29 – 1,372.44)

–*

 Colon and rectum cancers

160.31 (126.24–180.29)

0.0

0.0

1.1

16.9

71.9

70.3

90.85 (66.16–104.65)

69.46 (50.39–82.73)

2,323.71 (1,897.63 – 2,571.55)

1,399.22 (1,060.67 – 1,580.73)

924.49 (704.14 – 1,098.13)

 Mouth cancer

13.87 (11.62–16.79)

0.0

0.0

0.1

3.7

6.2

3.6

10.33 (8.48–13.11)

3.54 (2.14–4.85)

282.8 (236.88–352.29)

230.16 (187.58–298.5)

52.65 (31.34–70.41)

 Nasopharynx cancer

2.61 (1.64–3.53)

0.0

0.0

0.0

0.8

1.2

0.5

1.96 (1.14–2.91)

0.65 (0.31–1.05)

62.2 (39.43–87.48)

49.32 (29.12–74.66)

12.88 (6.14–19.83)

 Cancer of other part of pharynx and oropharynx

8.63 (4.93–11.43)

0.0

0.0

0.0

3.2

4.1

1.2

7.5 (4.12–10.7)

1.13 (0.48–1.83)

206.07 (118.56–292.36)

185.2 (104.09–277.98)

20.87 (8.52–33.12)

 Gallbladder and biliary tract cancer

19.93 (13.61–30.72)

0.0

0.0

0.0

1.4

9.3

9.0

7.04 (4.22–11.03)

12.89 (7.14–22.96)

269.16 (187.54–408.35)

107.66 (65.4–163.82)

161.5 (88.78–288.73)

 Pancreatic cancer

53.44 (38.17–70.44)

0.0

0.0

0.3

7.6

27.4

18.0

27.66 (17.79–36.7)

25.78 (15.56–39.61)

875.5 (637.54 – 1,113.72)

517.94 (335.01–680.03)

357.56 (215.21–544.31)

 Malignant melanoma of skin

9.36 (5.58–13.09)

0.0

0.0

0.5

2.2

3.8

2.7

5.14 (2.28–8.31)

4.22 (2.23–6.97)

198.46 (125.2–285.93)

114.49 (55.15–197.21)

83.97 (46.36–131.3)

 Non-melanoma skin cancer

6.79 (4.12–11.36)

0.0

0.0

0.0

0.3

1.6

4.7

3.57 (1.72–6.74)

3.23 (1.42–7.1)

72.93 (44.47–125.29)

46.17 (22.35–90.37)

26.75 (11.84–56.5)

 Ovarian cancer

21.15 (13.35–27.17)

0.0

0.0

0.4

5.0

10.1

5.6

–*

21.15 (13.35–27.17)

415.83 (277.13–553.19)

–*

415.83 (277.13–553.19)

 Testicular cancer

0.66 (0.32–1.1)

0.0

0.0

0.0

0.0

0.0

0.1

0.66 (0.32–1.1)

–*

21.3 (11.38–31.3)

21.3 (11.38–31.3)

–*

 Kidney and other urinary organ cancers

34.18 (24.57–56.41)

0.0

0.0

0.2

5.2

16.8

11.8

21.44 (14.98–41.31)

12.74 (7.01–23.93)

574.91 (420.5–941.19)

385.7 (278.74–736.03)

189.21 (108.55–335.81)

 Bladder cancer

49.77 (34.6–60.6)

0.0

0.0

0.0

3.6

22.1

24.1

39.86 (24.7–50.26)

9.91 (7.13–13)

654.29 (461.6–771.51)

549.7 (357.15–673.67)

104.6 (77.76–128.75)

 Brain and nervous system cancers

35.98 (19.75–47.79)

0.0

0.9

2.0

8.4

17.2

7.5

19.01 (7.63–26.36)

16.96 (6.63–25.86)

830.9 (476.65 – 1,032.05)

470.77 (201.2–635.62)

360.13 (155.29–483.64)

 Thyroid cancer

3.59 (2.59–4.71)

0.0

0.0

0.0

0.3

1.7

1.4

1.2 (0.67–1.73)

2.39 (1.48–3.39)

57.39 (42.19–73.87)

23.49 (12.68–33.42)

33.91 (21.28–47.35)

 Hodgkin's disease

2.65 (1.69–3.95)

0.0

0.0

0.3

0.4

1.1

0.6

1.43 (0.72–2.35)

1.22 (0.6–2.06)

70.16 (46.16–106.97)

41.58 (21.53–69.86)

28.59 (14.86–49.59)

 Non-Hodgkin lymphoma

27.11 (17.91–33.76)

0.0

0.0

1.0

4.0

12.6

9.3

14.12 (8.57–17.92)

12.98 (6.48–17.22)

487.31 (353.12–563.21)

283.95 (184.07–336.15)

203.35 (113.58–246.19)

 Multiple myeloma

17.81 (11.24–25.25)

0.0

0.0

0.0

1.6

9.7

6.4

8.93 (4.6–15.05)

8.88 (4.49–14.08)

267.24 (175.37–381.15)

142.53 (75.4–242.08)

124.71 (64.53–196.93)

 Leukemia

39.1 (27.64–48.47)

0.0

0.9

1.5

3.8

16.3

16.6

22.79 (13.64–28.19)

16.31 (8.25–23.37)

672.27 (529–803.1)

406.11 (272.07–491.1)

266.16 (149.02–354.36)

 Other neoplasms

84.59 (64.71–111.97)

0.0

0.8

2.2

11.6

37.0

32.9

45.63 (29.95–69.82)

38.96 (25.69–58.6)

1,442.11 (1,134.05 – 1,965.74)

850.47 (589.15 – 1,306.45)

591.64 (403.56–900.02)

Cardiovascular and circulatory diseases

1,411.99 (1,323.93 – 1,541.5)

0.2

0.9

9.8

70.4

374.6

956.1

621.16 (583.59–657.16)

790.83 (714.8–921.4)

1,4937.05 (1,4229.38 – 1,6134.05)

8,344.88 (7,929.4 – 8,713.27)

6,592.17 (6,047.73 – 7,708.66)

 Rheumatic heart disease

36.79 (29.03–45.78)

0.0

0.0

0.1

1.3

9.4

25.7

8.77 (5.83–11.22)

28.02 (21.11–36.12)

368.29 (308.32–428.92)

117.17 (78.95–138.38)

251.12 (204.52–302.84)

 Ischemic heart disease

626.56 (577.22–692.18)

0.0

0.1

4.9

40.2

178.0

403.3

308.45 (282.37–349.41)

318.11 (282.55–370.95)

7,081 (6,637.38 – 7,802.67)

4,428.89 (4,114.2 – 4,977.74)

2,652.11 (2,409.27 – 3,107.44)

 Cerebrovascular disease

429.4 (368.79–561.38)

0.0

0.1

1.9

14.0

103.2

310.0

171.63 (142.42–222.99)

257.77 (213.81–366.07)

4,112.36 (3,640.69 – 5,216.74)

2,003.92 (1,732.92 – 2,516.07)

2,108.44 (1,807.93 – 2,964.23)

 Hypertensive heart disease

63.64 (47.68–83.36)

0.0

0.0

0.1

1.6

12.9

48.8

21.25 (15.45–26.68)

42.38 (27.82–62.1)

566.48 (445.62–709.6)

242.98 (183.82–285.61)

323.5 (216.24–460.26)

 Cardiomyopathy and myocarditis

50.88 (43.67–60.5)

0.0

0.0

1.1

4.8

16.3

28.4

28.21 (22.58–36.59)

22.67 (18.15–27.22)

697.3 (611.01–826.99)

470.92 (389.76–589.69)

226.37 (192.37–257.76)

 Atrial fibrillation and flutter

49.57 (29.32–78.88)

0.0

0.0

0.0

0.3

8.8

40.5

16.36 (8.17–30.95)

33.21 (16.15–60.01)

388.35 (250.38–588.8)

156.64 (84.08–278.6)

231.71 (129.37–389.33)

 Aortic aneurysm

22.1 (16.23–29.05)

0.0

0.0

0.1

1.8

9.8

10.2

16.99 (11.53–23.56)

5.11 (3.65–8.83)

308.17 (224.6–403.06)

251.95 (169.97–345.83)

56.22 (45.13–84.66)

 Peripheral vascular disease

13.51 (7.89–21.83)

0.0

0.0

0.0

0.1

2.8

10.5

4.27 (1.77–8.98)

9.24 (4.84–16.38)

113.92 (69.2–182.18)

49.4 (20.22–100.5)

64.52 (37.27–112.09)

 Endocarditis

4.85 (3.53–5.85)

0.0

0.0

0.0

0.3

1.6

2.6

2.32 (1.68–2.94)

2.53 (1.48–3.34)

68.91 (52.71–80.35)

39.65 (30.25–47.19)

29.26 (17.32–36.84)

 Other cardiovascular and circulatory diseases

114.69 (103.64–128.09)

0.0

0.0

1.1

5.2

31.8

76.3

42.9 (38.16–47.72)

71.79 (61.6–84.61)

1,232.26 (1,151.54 – 1,317.41)

583.36 (538.22–631.15)

648.9 (582.6–724.27)

Chronic respiratory diseases

314.29 (290.3–340.56)

0.0

0.0

0.9

7.7

85.1

220.4

184.71 (168.12–201.48)

129.58 (112.04–149.2)

3,042.65 (2,862.02 – 3,232.05)

1,988.91 (1,853.32 – 2,124.11)

1,053.75 (943.48 – 1,173.44)

 Chronic obstructive pulmonary disease

186.69 (161.55–210.12)

0.0

0.0

0.1

4.1

54.2

128.0

127.89 (102.9–151.05)

58.8 (51.86–66.3)

1,816.89 (1,581.96 – 2,035.79)

1,350.53 (1,113.46 – 1,566.59)

466.36 (424.85–510.99)

 Pneumoconiosis

14.55 (9.49–21.14)

0.0

0.0

0.0

0.3

4.1

10.1

8.41 (4.68–13.84)

6.14 (3.08–10.78)

142.94 (95.3–207.26)

95.76 (55.91–154.49)

47.18 (24.97–78.07)

 Asthma

10.82 (8.31–14.66)

0.0

0.0

0.0

0.5

3.0

7.0

2.48 (1.66–5.71)

8.34 (5.6–10.39)

126.37 (103.62–173.86)

39.76 (28.92–83.48)

86.61 (61.65–101.64)

 Interstitial lung disease and pulmonary sarcoidosis

19.91 (12.32–29.59)

0.0

0.0

0.0

1.0

8.9

10.0

10.94 (5.81–19.32)

8.98 (4.04–15.82)

246.47 (167.1–353.69)

145.14 (85.09–237.34)

101.33 (52.57–165.72)

 Other chronic respiratory diseases

82.32 (60.89–108.12)

0.0

0.0

0.2

1.6

14.9

65.3

34.99 (24.62–53.3)

47.32 (30.81–69.1)

709.98 (577.64–969.25)

357.72 (274.56–541.95)

352.26 (248.4–502.74)

Cirrhosis of the liver

88.53 (77.98–111.17)

0.0

0.0

2.1

21.5

37.6

27.3

54.89 (46.88–74.57)

33.64 (27.92–44.82)

1,735.13 (1,547.01 – 2,184.28)

1,222.34 (1,061.28 – 1,660.84)

512.79 (438.15–732.49)

 Cirrhosis of the liver secondary to hepatitis B

3.68 (3.06–4.61)

0.0

0.0

0.0

0.8

1.6

1.2

1.93 (1.5–2.69)

1.74 (1.33–2.27)

66.56 (55.74–85.12)

40.9 (31.63–56.41)

25.66 (19.88–34.09)

 Cirrhosis of the liver secondary to hepatitis C

38.7 (32.55–49.19)

0.0

0.0

0.4

7.2

17.5

13.6

18.92 (14.59–26.86)

19.78 (15.03–26.26)

672.7 (569.42–857.44)

389.74 (303.2–550.58)

282.96 (221.68–386.87)

 Cirrhosis of the liver secondary to alcohol use

38.53 (32.41–50.61)

0.0

0.0

1.1

10.9

15.9

10.6

29.81 (23.69–41.15)

8.72 (6.93–11.34)

812.93 (675.37 – 1,067.51)

676.87 (540.63–931.27)

136.05 (110.95–182.42)

 Other cirrhosis of the liver

7.62 (6.34–9.58)

0.0

0.0

0.4

2.7

2.5

1.9

4.24 (3.29–6)

3.39 (2.63–4.49)

182.95 (152.89–235.21)

114.82 (89.6–162.57)

68.12 (53.84–96.43)

Digestive diseases (except cirrhosis)

129.05 (111.24–145.99)

0.0

0.0

0.9

6.1

35.4

86.5

54.43 (41.68–65.06)

74.62 (62.01–87.51)

1,367.61 (1,200.26 – 1,524.33)

712.46 (566.44–835.42)

655.16 (575.25–735.08)

 Peptic ulcer disease

7.94 (6.12–12.78)

0.0

0.0

0.0

0.5

2.3

5.0

3.91 (2.75–6.09)

4.03 (2.78–7.21)

94.36 (78.41–133.23)

56.52 (42.89–76.76)

37.84 (29.6–60.57)

 Gastritis and duodenitis

0.7 (0.38–1.34)

0.0

0.0

0.0

0.0

0.0

0.5

0.33 (0.15–0.79)

0.37 (0.17–0.83)

7.71 (4.66–14)

4.37 (2.43–9.64)

3.34 (1.85–6.94)

 Appendicitis

2.27 (1.25–3.37)

0.0

0.0

0.0

0.0

0.8

1.2

0.99 (0.39–1.73)

1.28 (0.51–2.11)

29.43 (17.11–40.96)

15.49 (6.22–24.66)

13.94 (5.89–20.06)

 Paralytic ileus and intestinal obstruction without hernia

18.65 (11.22–27.18)

0.0

0.0

0.0

0.3

4.2

13.9

6.75 (3.24–10.65)

11.89 (6.27–19.31)

168.81 (105.79–226.43)

73.98 (37.43–107.19)

94.82 (52.72–141.84)

 Inguinal or femoral hernia

1.98 (1.78–2.05)

0.0

0.0

0.0

0.0

0.4

1.4

0.87 (0.67–0.91)

1.11 (1.07–1.16)

19.83 (17.64–20.41)

10.61 (8.46–10.99)

9.22 (9–9.53)

 Non-infective inflammatory bowel disease

3.44 (2.08–4.92)

0.0

0.0

0.0

0.0

1.0

2.1

1.38 (0.77–2.01)

2.05 (1.08–3.31)

42.73 (27.98–55.05)

21.53 (12.89–28.54)

21.2 (12.37–30.96)

 Vascular disorders of intestine

31.9 (17.39–57.23)

0.0

0.0

0.0

0.9

8.9

21.9

14.29 (3.42–38.48)

17.61 (7.83–28.97)

311.86 (164.05–601.7)

170.18 (41.36–457.84)

141.68 (65.87–231.55)

 Gall bladder and bile duct disease

17.51 (12.19–24.68)

0.0

0.0

0.0

0.3

3.9

13.0

6.69 (3.94–10.06)

10.82 (6.51–17.59)

162.17 (122.46–210.64)

74.29 (46.15–103.25)

87.88 (57.82–129.7)

 Pancreatitis

13.45 (9.97–17.26)

0.0

0.0

0.2

1.5

4.7

7.0

6.36 (4.13–9.22)

7.08 (4.72–10.08)

190.96 (146.04–250.94)

113.47 (77.21–169.87)

77.5 (54.84–111.18)

 Other digestive diseases

31.22 (21.1–39.68)

0.0

0.0

0.1

1.6

8.9

20.4

12.85 (8.58–16.52)

18.36 (9.95–26.55)

339.75 (246.38–418.1)

172.02 (118.95–215.82)

167.73 (90.77–234.96)

Neurological disorders

298.8 (200.34–394.65)

0.3

0.7

1.7

6.5

64.8

224.8

109.69 (77.39–153.19)

189.11 (95.13–279.64)

2,744.5 (2,092.35 – 3,423.72)

1,220.72 (953.14 – 1,606.4)

1,523.78 (921.34 – 2,077)

 Alzheimer's disease and other dementias

243.35 (144.54–342.54)

0.0

0.0

0.0

1.0

44.2

198.0

81.11 (52.94–126.3)

162.24 (67.03–254.46)

1,877.24 (1,253.43 – 2,491)

729.99 (507.22 – 1,079.75)

1,147.26 (548.76 – 1,699.76)

 Parkinson's disease

29.53 (18.66–40.27)

0.0

0.0

0.0

0.1

9.3

19.8

14.86 (7.69–21.9)

14.67 (7.22–22.47)

274.27 (188.02–366.69)

151.03 (87.14–227.06)

123.24 (69.48–176.67)

 Epilepsy

4.82 (3.25–6.35)

0.0

0.0

0.4

0.8

1.2

2.0

2.47 (1.6–3.31)

2.36 (1.25–3.71)

108.12 (77.25–127.15)

64.85 (42.33–82.13)

43.27 (27.22–55.03)

 Multiple sclerosis

1.95 (1.42–2.48)

0.0

0.0

0.0

0.8

0.7

0.2

0.83 (0.54–1.11)

1.12 (0.7–1.57)

54.54 (39.84–70)

23.21 (15.26–31.31)

31.33 (19.49–44.75)

 Other neurological disorders

19.16 (12.14–26.18)

0.3

0.3

0.9

3.5

9.2

4.7

10.43 (5.95–15.79)

8.73 (3.82–14.32)

430.33 (278.35–593.29)

251.65 (149.6–392.18)

178.69 (80.22–282.85)

Mental and behavioral disorders

13.49 (9.72–21.5)

0.0

0.1

3.9

4.2

3.2

2.2

10.37 (7.15–18.63)

3.13 (1.83–4.34)

453.07 (323.04–797.96)

375.8 (253.67–729)

77.26 (48.94–109.57)

 Schizophrenia

1.17 (0.61–1.69)

0.0

0.0

0.0

0.0

0.4

0.4

0.61 (0.27–0.9)

0.56 (0.22–0.99)

22.53 (12.28–29.9)

13.51 (6.02–19.24)

9.02 (3.73–13.98)

 Alcohol use disorders

4.36 (2.61–8.97)

0.0

0.0

0.2

2.0

1.7

0.4

3.82 (2.05–8.28)

0.55 (0.22–1.13)

124.99 (77.51–260.19)

109.43 (61.15–243.7)

15.57 (6.05–31.99)

 Drug use disorders

6.98 (3.87–12.75)

0.0

0.1

3.3

2.0

0.6

0.8

5.52 (2.66–10.82)

1.47 (0.54–2.24)

291.52 (165.61–588.06)

245.59 (124.78–541.19)

45.92 (21.12–72.44)

 Eating disorders

0.29 (0.09–0.53)

0.0

0.0

0.0

0.0

0.0

0.2

0.1 (0.02–0.2)

0.19 (0.05–0.39)

4.53 (2.04–6.56)

1.77 (0.6–2.79)

2.76 (1.07–4.43)

 Other mental and behavioral disorders

0.69 (0.22–1.23)

0.0

0.0

0.0

0.0

0.0

0.4

0.32 (0.08–0.59)

0.37 (0.08–0.77)

9.5 (3.94–14.28)

5.5 (1.79–8.61)

3.99 (1.36–7.01)

Diabetes, urogenital, blood, and endocrine diseases

280.14 (242.63–353.84)

0.3

0.9

2.2

11.2

79.6

185.6

122.76 (103.65–167.15)

157.38 (128.53–205.29)

3,032.98 (2,645.05 – 4,078.86)

1,571.2 (1,318.85 – 2,311.61)

1,461.78 (1,239.48–1,988.42)

 Diabetes mellitus

112.02 (93.98–151.69)

0.0

0.0

0.2

3.9

34.7

73.3

44.69 (36.31–64.25)

67.33 (53.47–95.38)

1,146.26 (995.43 – 1,592.83)

561.77 (479.06–867.39)

584.49 (484.08–889.93)

 Acute glomerulonephritis

0.12 (0.06–0.2)

0.0

0.0

0.0

0.0

0.0

<0.1

0.07 (0.03–0.13)

0.05 (0.02–0.1)

2.5 (1.13–3.85)

1.55 (0.61–2.75)

0.95 (0.33–1.55)

 Chronic kidney diseases

84.59 (67.95–110.54)

0.0

0.0

0.2

2.4

21.6

60.0

40.03 (32.54–56.18)

44.56 (30.42–67.37)

819.87 (698.77 – 1,098.83)

434.71 (369.26–647.87)

385.15 (289.79–590.98)

 Urinary diseases and male infertility

44.35 (26.86–63.32)

0.0

0.0

0.0

1.1

10.8

32.0

21.01 (10.9–33.29)

23.34 (11.35–38.22)

422.38 (270.67–566.13)

222.07 (121.63–335.67)

200.31 (108.39–294.38)

 Gynecological diseases

0.35 (0.3–0.39)

0.0

0.0

0.0

0.0

0.0

0.2

–*

0.35 (0.3–0.39)

5.16 (3.99–6.54)

–*

5.16 (3.99–6.54)

 Hemoglobinopathies and hemolytic anemia

5.12 (3.77–7.24)

0.0

0.0

0.0

0.0

1.3

3.3

1.89 (1.27–3.33)

3.23 (2.15–4.79)

63.28 (49.79–89.97)

28.65 (21.48–47.37)

34.63 (24.75–52.35)

 Other endocrine, nutritional, blood, and immune disorders

33.6 (20.57–84.45)

0.3

0.8

1.3

3.4

11.0

16.8

15.07 (7.43–50.5)

18.52 (9.54–47.65)

573.52 (378.68–1356.21)

322.44 (178.48–991.18)

251.08 (145.49–542.18)

Musculoskeletal disorders

39.06 (25.64–66.48)

0.0

0.0

0.3

1.5

7.9

29.3

13.39 (7.92–29.58)

25.67 (14.36–48.24)

375.55 (268.26–613.79)

143.94 (96.43–294.08)

231.6 (141.74–414.1)

 Rheumatoid arthritis

2.89 (1.98–4.19)

0.0

0.0

0.0

0.1

1.5

1.1

0.65 (0.36–0.91)

2.24 (1.42–3.54)

44.56 (31.57–68.08)

11.65 (6.79–15.99)

32.91 (22–57.69)

 Other musculoskeletal disorders

36.17 (23.93–62.55)

0.0

0.0

0.2

1.3

6.5

28.2

12.74 (7.32–28.65)

23.43 (13.07–42.38)

330.99 (241.09–564.59)

132.3 (86.48–278.21)

198.69 (129.47–310.74)

Other non-communicable diseases

26.82 (21.12–32.38)

4.9

1.3

1.1

1.7

4.1

13.7

10.76 (8.68–13.33)

16.06 (11.32–21.15)

793.69 (700.07–998.5)

408.18 (349.11–554.42)

385.51 (323.19–522.23)

 Congenital anomalies

15.23 (12.89–18.32)

4.2

1.3

1.1

1.5

2.0

5.3

6.84 (5.66–8.92)

8.38 (6.41–10.77)

637.65 (561.04–826.64)

336.37 (283.44–482.44)

301.28 (254.05–437.58)

 Skin and subcutaneous diseases

10.88 (6.36–15.66)

0.0

0.0

0.0

0.0

2.2

8.4

3.53 (1.83–5.17)

7.36 (3.26–11.69)

94.99 (60.79–124.7)

37.8 (22.51–50.55)

57.19 (28.45–83.86)

 Sudden infant death syndrome

0.71 (0.37–1.3)

0.7

0.0

0.0

0.0

0.0

0.0

0.4 (0.16–0.89)

0.31 (0.12–0.74)

61.05 (31.43–111.36)

34 (14.13–76.52)

27.04 (10–63.55)

Injuries

170.04 (148.35–187.71)

0.3

6.1

29.5

34.1

41.7

58.4

106.22 (90.64–120.45)

63.81 (51.39–76.28)

4,467.58 (3,963.64 – 4,986.31)

3,292.76 (2,796.78 – 3,744.15)

1,174.82 (1,034.86 – 1,351.47)

Transport injuries

43.13 (37.17–58.97)

0.1

3.6

12.6

11.0

10.4

5.4

31.86 (25.72–45.25)

11.27 (9.3–16.49)

1,619.03 (1,392.59 – 2,120.51)

1,251.7 (1,009.35 – 1,695.55)

367.33 (311.6–513.85)

 Road injury

39.5 (34.03–54.39)

0.0

3.5

11.9

9.9

9.3

4.9

28.91 (23.7–41.92)

10.59 (8.9–16.96)

1,495.72 (1,292.76 – 1,960.84)

1,151.98 (940.51 – 1,613.62)

343.74 (298.04–519.39)

 Other transport injury

3.63 (2.55–4.38)

0.0

0.1

0.9

1.1

1.2

0.5

2.95 (1.89–3.64)

0.68 (0.41–0.94)

123.31 (84.2–148.87)

99.72 (65–123.8)

23.59 (13.19–31.95)

Unintentional injuries other than transport injuries

86.75 (66.99–104.08)

0.2

1.5

7.1

10.1

20.6

47.2

44.43 (34.25–53.05)

42.32 (29.03–55.39)

1,528.68 (1,254.66 – 1,728.1)

1,042.66 (815 – 1,229.43)

486.02 (376.59–575.11)

 Falls

30.18 (18.17–39.84)

0.0

0.1

1.5

2.9

7.5

18.0

14.31 (7.51–19.64)

15.87 (8.02–23.56)

447.58 (283.13–557.46)

290.71 (160.9–367.9)

156.87 (86.49–210.64)

 Drowning

6 (4.88–7.84)

0.0

0.5

1.3

1.6

1.8

0.8

4.75 (3.71–6.73)

1.24 (0.93–1.72)

211.72 (171.89–283.97)

174.93 (136.46–247.02)

36.79 (28.15–50.44)

 Fire, heat, and hot substances

3.68 (2.88–5.15)

0.0

0.0

0.1

0.4

0.9

1.9

1.91 (1.41–2.8)

1.78 (1.2–2.94)

70.8 (57.89–97.19)

45.6 (33.42–69.01)

25.2 (18.93–38.16)

 Poisoning

4.4 (2.11–6.11)

0.0

0.0

1.6

1.2

0.6

0.8

2.98 (1.07–4.44)

1.42 (0.61–1.99)

158.83 (71.04–225.89)

120.96 (40.98–185.67)

37.88 (18.83–49.55)

 Exposure to mechanical forces

3.13 (1.83–4.37)

0.0

0.0

0.7

1.1

0.7

0.4

2.59 (1.37–3.91)

0.54 (0.21–0.84)

110.16 (64.39–170.53)

97.15 (52.91–157.16)

13.01 (6.3–17.41)

 Adverse effects of medical treatment

9.25 (5.89–14.86)

0.0

0.0

0.0

0.8

3.0

5.2

3.72 (2.85–4.92)

5.53 (2.38–11.18)

124.7 (92.38–189.32)

61.82 (50.93–75.98)

62.88 (32.01–124.6)

 Animal contact

0.23 (0.16–0.33)

0.0

0.0

0.0

0.0

0.0

<0.1

0.17 (0.1–0.25)

0.06 (0.03–0.1)

6.95 (4.67–10.13)

5.57 (3.3–8.48)

1.38 (0.82–2.26)

Unintentional injuries not classified elsewhere

29.87 (20.72–40.43)

0.1

0.1

1.4

2.2

6.0

20.1

14 (10.17–19.39)

15.87 (7.88–25.14)

397.93 (328.14–565.3)

245.92 (194.62–407.48)

152.01 (106.27–205.69)

 Self-harm and interpersonal violence

40.16 (29.92–51.78)

0.0

0.6

9.9

12.9

10.7

5.8

29.94 (20.81–40.68)

10.22 (7.11–14.48)

1,319.87 (925.79 – 1,566.26)

998.4 (662.08–1251.41)

321.47 (206.88–412.94)

 Self-harm

35.73 (25.84–47.01)

0.0

0.5

8.2

11.5

10.0

5.4

26.91 (17.67–37.57)

8.82 (5.95–13.1)

1,139.19 (743.97 – 1,364.03)

870.51 (539.56 – 1,112.22)

268.69 (162.15–360.64)

 Interpersonal violence

4.43 (3.28–6.27)

0.0

0.1

1.7

1.4

0.7

0.4

3.03 (1.99–4.87)

1.4 (1–1.69)

180.68 (131.92–255.73)

127.9 (81.49–197.53)

52.78 (36.94–63.05)

Data are presented as mean values and uncertainty intervals (Lower, Upper).

Mortality’s uncertainty intervals in the six age groups (original age groups are 20) are not included in the table and will be given upon request.

*– not applicable.

Age-specific analysis revealed that non-communicable diseases remained the major cause of mortality except for children below 1 year of age. Cardiovascular- and circulatory-related mortality raised with ageing, from 6% of deaths in individuals younger than 20 years old to almost 41% in those 80 years old and over. Neoplasm-related mortality was almost 22% of deaths in individuals aged up to 40 years, nearly doubled in the group aged 40–79 years and finally dropped to 17% in the group of octogenarians. On the contrary, the main cause of mortality in newborns was communicable diseases, which accounted for 61.5% of all deaths within the group.

In regard to gender differences, the main cause of male mortality was neoplasms (33%), followed by cardiovascular diseases (30.3%), chronic respiratory diseases (9.5%), neurological diseases (5.3%), and injuries (5.2%). On the other hand, the main cause of female mortality were cardiovascular diseases (39.4%) followed by neoplasms (21.4%), neurological disorders (9.4%), and the group formed by diabetes, urogenital, blood, and endocrine diseases (7.8%) (Figure 1).
Figure 1

Spanish deaths in 2010 for males (204,990 total deaths) and females (200,750 total deaths) at all ages.

As shown in Table 2, 86% of total YLLs were due to non-communicable diseases, with injuries and communicable diseases accounting for 8% and 6%, respectively (see specific ranking in Figure 2). In 2010, regardless of gender, the leading specific cause for YLLs was neoplasms followed by cardiovascular and circulatory diseases.
Figure 2

Spanish years of life lost (YLLs) ranks for the top 20 main causes in 1990 and 2010, and the percentage change between 1990 and 2010. Solid line for increase or equal position. Continuous line represents an ascending order in rank and the broken line represents a descending order. (Δ%) = % of change in absolute numbers of DALYs.

In the top twenty causes of YLLs, the ranking (% of change between the number of YLLs) changed between 1990 and 2010 (Figure 2). Remarkably, due to a large decrease in the number of YLLs, cardiovascular and circulatory diseases dropped from the first cause in 1990 to the second cause of YLLs in 2010 (decreased by 18%). Neoplasms were the leading cause in 2010 (the second in 1990), and increased almost 12% in 2010 compared to 1990. Transport injuries were the seventh cause (third in 1990), and the chronic respiratory diseases were the third cause (fourth in 1990). Unintentional injuries other than transport injuries were the eighth cause (fifth in 1990), and decreased by approximately 46% since 1990. Diabetes, urogenital, blood, and endocrine diseases were the fourth cause (sixth in 1990), increasing by almost 10%. The burden of YLLs in 2010, attributable to cirrhosis of the liver as well as diarrhea, lower respiratory infections, meningitis, and other common infectious diseases, decreased compared with 1990 (seventh to sixth cause and eight to ninth position, respectively). The percentage of YLLs attributable to self-harm and interpersonal violence, neonatal disorders, other non-communicable diseases, and HIV/AIDS and tuberculosis, decreased by almost 9%, 32%, 35%, and 55% between 1990 and 2010, respectively. In contrast, YLLs attributable to neurological disorders increased by 134% and were the fifth leading cause in 2010, while YLLs due to mental and behavioral disorders increased by 29% between 1990 and 2010 (Figure 2).

Table 3 presents all causes of DALYs and YLDs in the Spanish population between 1990 and 2010. In this 20-year period, there was an increase in the overall burden of YLDs of almost 26%. In the broader classification terms (between 1990 and 2010), musculoskeletal disorders, mental and behavioral disorders, and diabetes, urogenital, blood, and endocrine diseases were the three main contributors to the years lived with disability in Spain. Focusing only in 2010, the largest contributors to the burden of YLDs, were the musculoskeletal disorders (26%) and the mental and behavioral disorders (22%). The group of diabetes, urogenital, blood, and endocrine disorders had an important contribution to the burden of disability (10%), followed by the group of other non-communicable disorders (9%), neurological disorders (8%), and other unintentional injuries except for transportation injuries (7%).
Table 3

Comparison of the main causes of disability-adjusted life years (DALYs) and years lived with disability (YLDs), in 1990 and 2010, for the Spanish population

YLDs (hundreds)

DALYs (hundreds)

 

1990

2010

% Δ

1990

2010

% Δ

All causes

44,316.8

55,706.6

25.7%

104,615.9

110,269.4

5.4%

Communicable, maternal, neonatal, and nutritional disorders

1,914.7 (1,415.3–2,628.9)

1,942.5 (1,377.8–2,767.8)

1%

6,394.8 (5,773.6–7,126)

5,067.4 (4,450.8–5,848.2)

−21%

HIV/AIDS and tuberculosis

285.4 (202.5–384.5)

183 (128.5–248.3)

−36%

1,532.1 (1,356.2–1,720.5)

738.3 (643.6–844.3)

−52%

  Tuberculosis

114.8 (71.7–171.8)

84.4 (50.8–129.2)

−26%

340.6 (274–409.3)

175.9 (136.8–230.7)

−48%

  HIV/AIDS

170.6 (123.2–223.1)

98.6 (70.8–131.4)

−42%

1,191.6 (1,042–1,360.4)

562.4 (478.8–651.9)

−53%

  HIV disease resulting in mycobacterial infection

12.1 (6.7–19.4)

4.7 (2–8.3)

−62%

59.8 (51.5–69.1)

19.6 (16–24.1)

−67%

  HIV disease resulting in other specified or unspecified diseases

158.4 (114.2–206.7)

93.9 (67.9–125.4)

−41%

1,131.7 (993.6–1,271.3)

542.8 (469.8–629.4)

−52%

Diarrhea, lower respiratory infections, meningitis, and other common infectious diseases

858.5 (590.7–1249)

925.1 (621.7–1339.5)

8%

2,555.5 (2,206.4–3,004.8)

2,358.1 (1,992.4–2,814.4)

−8%

  Diarrheal diseases

306.2 (201.3–440.4)

363.2 (238.6–520.2)

19%

358.6 (252.5–493.1)

428.9 (305.6–585.7)

20%

  Typhoid and paratyphoid fevers

0 (0–0.1)

0 (0–0.1)

27%

1.1 (0.1–2)

1 (0.1–2)

−4%

  Lower respiratory infections

44.3 (29.7–62)

48.4 (33–66.8)

9%

1391.6 (1227.5–1612.5)

1,275.9 (1,096–1,523.9)

−8%

  Upper respiratory infections

219.3 (106.2–390.9)

227.8 (110.9–429.7)

4%

221 (107.8–392.7)

228.4 (111.5–430.3)

3%

  Otitis media

211.6 (127.1–339.9)

211.9 (120.7–361)

0.2%

213.6 (127.9–341.7)

213.3 (123–363.3)

0%

  Meningitis

52.1 (33.7–77.9)

46.8 (29–71.8)

−10%

261.9 (229.8–309)

153.7 (129.1–183.3)

−41%

  Pneumococcal meningitis

10.2 (6.2–15.4)

6.7 (3.8–10.6)

−34%

39.8 (33.2–47.3)

21.8 (17.6–26.7)

−45%

  H influenza type B meningitis

7.4 (4.3–11.8)

3.1 (1.6–5.1)

−58%

33.7 (27.2–42.1)

13.6 (10.8–17.3)

−60%

  Meningococcal infection

16.6 (10.2–25.7)

14.6 (8.4–23.2)

−12%

88.8 (75.5–106.7)

50.1 (40.9–61.3)

−44%

  Other meningitis

17.2 (10.9–26.6)

21.8 (13.3–33.6)

27%

99 (86–116.3)

67.7 (55.6–82.7)

−32%

  Encephalitis

5.6 (3.3–8.7)

5.5 (3.2–9)

−1%

28.5 (24.7–32.7)

17.9 (14.7–21.8)

−37%

  Diphtheria

0 (0–0)

0 (0–0)

−82%

0.9 (0–7.3)

0.3 (0–2.5)

−66%

  Whooping cough

2.4 (1.3–3.8)

0.6 (0.3–1.1)

−74%

47.8 (2.3–221.4)

9.3 (0.6–40.9)

−81%

  Tetanus

0 (0–0)

0 (0–0)

−69%

3.4 (0.4–13)

0.7 (0.1–2.6)

−80%

  Measles

0.8 (0.3–1.4)

0 (0–0.1)

−99%

4 (2.2–6.4)

1.5 (0.7–3.9)

−62%

  Varicella

16.2 (8.2–29.1)

20.8 (10.1–39.2)

29%

23.3 (9.2–63.2)

27.3 (11.6–67.5)

18%

Neglected tropical diseases and malaria

8.5 (2.3–21.8)

15.6 (2.5–51.2)

83%

69.6 (39.7–120.3)

64.9 (35.1–120.1)

−7%

  Malaria

0.5 (0–3.9)

0.1 (0–0.8)

−75%

0.5 (0–3.9)

0.1 (0–0.8)

−75%

  Leishmaniasis

1.3 (0.6–2.7)

1.4 (0.6–2.9)

6%

10.6 (7.4–14.7)

8.4 (5.8–11.5)

−21%

  *Cysticercosis

0 (0–0)

–*

–*

0.6 (0–2.2)

–*

–*

  Echinococcosis

5.3 (0.8–18.1)

7 (1–25.6)

32%

15.6 (2.2–47.7)

12.1 (2.1–35.5)

−22%

  Dengue

0 (0–0)

0 (0–0)

–*

31.8 (9.6–70.5)

30.9 (12.5–68.8)

−3%

  Rabies

0 (0–0)

0 (0–0)

13%

5.6 (2.7–12.4)

2 (1.1–3.9)

−64%

  Food-borne trematodiases

0.1 (0–0.4)

0.1 (0–0.3)

−31%

0.1 (0–0.4)

0.1 (0–0.3)

−31%

  Other neglected tropical diseases

1.3 (0.1–1.6)

7 (0.2–6.2)

425%

4.8 (2.5–7)

11.3 (3–11.7)

133%

Maternal disorders

14.1 (8.9–21.7)

12.5 (7.5–19.6)

−11%

37 (29–47.5)

28.7 (21.7–37.2)

−22%

  Maternal hemorrhage

5.9 (3.4–9.5)

5.3 (3–8.5)

−11%

10.3 (7.4–14)

8.5 (6–11.9)

−17%

  Maternal sepsis

0.3 (0–1)

0.3 (0–1)

−9%

1.3 (0.8–2.1)

0.9 (0.5–1.6)

−33%

  Hypertensive disorders of pregnancy

0.6 (0.3–1.1)

0.7 (0.3–1.2)

9%

3.9 (3–5.1)

2.9 (2.1–3.8)

−26%

  Obstructed labor

1.1 (0–3.4)

1.1 (0–3.4)

−2%

2 (0.9–4.3)

1.8 (0.7–4.2)

−12%

  Abortion

2 (1.1–3.4)

1.4 (0.7–2.5)

−29%

5.2 (3.9–6.8)

3.4 (2.4–4.6)

−35%

  Other maternal disorders

4.1 (2.6–6.2)

3.8 (2.3–5.8)

−8%

14.2 (11.1–18.1)

11.3 (8.4–14.4)

−21%

Neonatal disorders

224.6 (164.9–300.8)

218.4 (162.3–282.8)

−3%

1,468.3 (1,242.3–1,668.6)

1,061.2 (934.7–1,183)

−28%

  Preterm birth complications

96.4 (66.9–136.9)

109.4 (75.9–149.6)

13%

788.4 (627.9–938.5)

533 (433–665.9)

−32%

  Neonatal encephalopathy (birth asphyxia and birth trauma)

126.6 (89.5–172.7)

107 (77.3–143.6)

−15%

425.4 (336.5–527.3)

297.5 (235.6–375)

−30%

  Sepsis and other infectious disorders of the newborn baby

0.1 (0.1–0.3)

0.3 (0.2–0.6)

140%

110.1 (60.9–192.3)

111.2 (60–197.5)

1%

  Other neonatal disorders

1.4 (1–2)

1.7 (1.2–2.3)

16%

144.3 (91.2–262.3)

119.5 (67.1–179.2)

−17%

Nutritional deficiencies

444.6 (269.2–712.5)

507.8 (314.2–801.1)

14%

524.2 (347–797.2)

590.7 (394.4–885)

13%

  Protein-energy malnutrition

14.3 (9.3–21.2)

22.7 (14.8–31.8)

59%

46.2 (38.5–57.6)

75 (52.4–93.8)

62%

  Iodine deficiency

427.1 (251.8–694)

480.5 (285–763.7)

13%

428.8 (253.7–695.7)

482.4 (286.9–765.8)

13%

  Iron-deficiency anemia

1.1 (0.5–2)

3 (1–3.2)

171%

41.8 (35.4–54.5)

27.9 (16.9–33.7)

−33%

  Other nutritional deficiencies

2.2 (1.8–2.8)

1.5 (0.9–2)

−29%

7.5 (6.3–9.8)

5.3 (3.2–6.9)

−29%

Other communicable, maternal, neonatal, and nutritional disorders

79 (38.7–149.3)

80.1 (35.6–168.3)

1%

208 (161.6–281.2)

225.5 (162.4–323.7)

8%

  Sexually transmitted diseases excluding HIV

64.3 (29.6–128.4)

56.9 (26–114)

−11%

91.6 (56.3–157.8)

66.6 (35.2–123.7)

−27%

  Syphilis

3.9 (0.2–8.7)

4.8 (0.3–10.7)

21%

25.4 (15.7–39.3)

10.9 (5–18)

−57%

  Sexually transmitted chlamydial diseases

25.3 (8.7–60)

22.4 (7.6–53.6)

−12%

26.7 (10.1–61.5)

23.2 (8.3–54.3)

−13%

  Gonococcal infection

13.7 (5.2–30.2)

14.5 (5–32.7)

6%

14.8 (6.1–31.3)

15.1 (5.6–33.5)

2%

  Trichomoniasis

13.3 (0.1–41.8)

9.2 (0.1–29.1)

−31%

13.3 (0.1–41.8)

9.2 (0.1–29.1)

−31%

  Other sexually transmitted diseases

8 (2.9–18.1)

6 (2.5–12)

−25%

11.5 (6.2–21.5)

8.2 (4.5–14.2)

−29%

  Hepatitis

12.2 (6–21.9)

12.9 (6.2–22.8)

6%

67.3 (57.9–79)

66 (55.8–77.8)

−2%

  Acute hepatitis A

8.3 (3.9–14.7)

7.5 (3.7–13)

−9%

17 (11.2–24.8)

11 (6.5–17.6)

−35%

  Acute hepatitis B

2.8 (0.2–9.2)

3.4 (0.2–10.6)

21%

42.8 (26.3–55.3)

24 (12.6–43.4)

−44%

  Acute hepatitis C

1 (0.2–2.1)

2 (0.4–4.1)

87%

7.6 (2.8–15.8)

31 (10.5–53.4)

308%

  Leprosy

0.1 (0–0.1)

0 (0–0)

−87%

0.1 (0–0.1)

0 (0–0)

−87%

  Other infectious diseases

2.5 (0–0.3)

10.3 (0–0.4)

314%

49 (37.6–81.3)

92.8 (39.3–114.7)

89%

Non-communicable diseases

38,528.9 (32,278.2–45,503.6)

48,269.1 (40,257.6–56,616.6)

25%

86,260 (79,823.1–93,301.2)

95,239.4 (87,522.2–10,3475.6)

10%

Neoplasms

474.2 (349.1–630.6)

816.4 (597.6–1074.5)

72%

16,917.3 (16,102.7–17,858.3)

19,304.5 (18,003–20,302.6)

14%

  Esophageal cancer

3.2 (1.6–5.3)

3.6 (1.8–6.2)

10%

413.9 (310.3–535.2)

392.1 (290.6–538.8)

−5%

  Stomach cancer

24.3 (15.3–35.6)

21.2 (12.9–33)

−13%

1,443.2 (1,131–1,931.8)

1,007.9 (765–1,402.6)

−30%

  Liver cancer

6.5 (3.9–9.8)

9.6 (5.8–14.8)

47%

720 (581.5–818.5)

846.8 (712.5–1,044.6)

18%

  Liver cancer secondary to hepatitis B

0.9 (0.3–1.8)

1.3 (0.4–2.4)

38%

100.9 (80.1–116.3)

119.2 (97.8–152.4)

18%

  Liver cancer secondary to hepatitis C

2.8 (1.5–4.7)

3.9 (2–6.6)

40%

287.9 (236.3–332.2)

331.9 (277.3–427.1)

15%

  Liver cancer secondary to alcohol use

2.2 (1.1–3.7)

3.6 (1.9–5.9)

64%

253 (201.7–291.3)

301 (253–381)

19%

  Other liver cancer

0.6 (0.1–1.4)

0.8 (0.1–1.6)

26%

78.2 (62.9–90.4)

94.7 (74.6–116.3)

21%

  Larynx cancer

14 (7.3–24.9)

12.3 (6.5–23.3)

−12%

498.7 (252.2–859.6)

373.9 (202.3–685.2)

−25%

  Trachea, bronchus, and lung cancers

34.1 (22.3–49.5)

45.5 (25.9–64.2)

34%

3,138.8 (2,541.8–3,982.3)

3,686.7 (2,408.1–4,161.1)

17%

  Breast cancer

122.7 (80.8–187.9)

188.1 (120.8–277.2)

53%

1,496.8 (1,400.8–1,611.5)

1,469.4 (1,340.6–1,619.2)

−2%

  Cervical cancer

5.4 (2.9–8.7)

5.2 (2.7–8.6)

−4%

226.8 (143.3–321.6)

212.3 (135.6–306.1)

−6%

  Uterine cancer

10.9 (5.7–20.1)

13.6 (5.7–23.1)

24%

174.1 (100.8–316.1)

194.6 (93.5–271.9)

12%

  Prostate cancer

40.2 (27–60)

120.3 (78.9–185.9)

199%

609 (373.5–941.4)

939.3 (572.7–1,489.8)

54%

  Colon and rectum cancers

63.1 (44.8–85.4)

128.7 (90.3–171.7)

104%

1,675.7 (1,476.6–1,895.5)

2,452.4 (2,019.5–2,711)

46%

  Mouth cancer

12.4 (8.2–17.8)

13.8 (8.9–20.3)

12%

307.3 (257.8–337.4)

296.6 (250.1–367.2)

−3%

  Nasopharynx cancer

0.9 (0.3–1.9)

1 (0.3–2)

5%

70.2 (40.1–94.4)

63.2 (40.4–88.2)

−10%

  Cancer of other part of pharynx and oropharynx

4.1 (2–7)

5.8 (2.8–9.4)

42%

172.5 (100.3–251.3)

211.9 (125.8–299.5)

23%

  Gallbladder and biliary tract cancer

3.6 (1.9–6.1)

5.1 (2.5–9)

41%

253.9 (169.6–370.5)

274.3 (193–414.1)

8%

  Pancreatic cancer

3.9 (2–6.5)

6.3 (3.4–10.4)

63%

627.8 (480.8–812.9)

881.8 (646.5–1120.7)

40%

  Malignant melanoma of skin

4.2 (2.3–7.9)

8.6 (4.7–13.7)

103%

140.1 (94.4–223.2)

207.1 (133–294.9)

48%

  Non-melanoma skin cancer

15.6 (10.7–21.9)

38 (25.9–52.8)

143%

89.4 (55.1–125.3)

110.9 (80.5–165.1)

24%

  Ovarian cancer

6.2 (3.6–9.8)

9.4 (5.2–14.5)

52%

336.7 (252.6–453.1)

425.2 (287.4–561.8)

26%

  Testicular cancer

0.8 (0.2–1.6)

1.4 (0.5–2.9)

86%

22.9 (13.7–34.8)

22.7 (12.9–32.9)

−1%

  Kidney and other urinary organ cancers

5.6 (3.1–8.6)

17.7 (10.2–30.6)

218%

255.5 (178.9–327.2)

592.6 (435.2–958.7)

132%

  Bladder cancer

31.7 (21.7–43.9)

49.8 (32.2–69.6)

57%

617 (491.5–789.2)

704.1 (508.2–824.7)

14%

  Brain and nervous system cancers

11.5 (6.6–17.9)

17.4 (8.7–27.2)

51%

716.6 (488.1–1,011.1)

848.3 (492.4–1,050.7)

18%

  Thyroid cancer

2.5 (1.3–4.4)

4.1 (2.2–6.8)

63%

51.9 (40.5–66.8)

61.5 (45.7–78.9)

18%

  Hodgkin’s disease

2.4 (1–4.2)

2.1 (0.9–3.9)

−11%

112.8 (73.1–166.8)

72.3 (47.9–109.7)

−36%

  Non-Hodgkin’s lymphoma

9.4 (6–13.8)

16.1 (10–23.9)

72%

417.3 (366.4–493.7)

503.5 (364.3–578.3)

21%

  Multiple myeloma

5.4 (2.8–9)

8.3 (4.3–13.5)

55%

212.7 (146.8–305.2)

275.6 (182.9–388.8)

30%

  Leukemia

10.4 (6.7–15.4)

16.1 (10–23.5)

55%

705.9 (575.5–880)

688.4 (544.1–817)

−2%

  Other neoplasms

19.2 (12.4–28.5)

47.2 (30–69.8)

145%

1,409.8 (1,108.1–1,845.1)

1,489.3 (1,190.5–2,016.9)

6%

Cardiovascular and circulatory diseases

1,911.6 (1,475.9–2,423)

2,864.9 (2,268.9–3,499.4)

50%

20,076.7 (18,998.5–20,904.2)

17,802 (16,834.2–19,181.8)

−11%

  Rheumatic heart disease

125.4 (77.4–198.2)

139.1 (93.2–207.5)

11%

823.4 (745.2–933.8)

507.3 (429.5–599)

−38%

  Ischemic heart disease

737.6 (477.9–1108)

974.8 (636–1420.7)

32%

9,202.7 (8,705.1–9,952.4)

8,055.8 (7,462.7–8,876.3)

−12%

  Cerebrovascular disease

337.1 (278.1–393.5)

640.5 (529.3–755.2)

90%

6,437.3 (5,648.1–6,783.7)

4,752.8 (4,252.9–5,829.1)

−26%

  Ischemic stroke

271.4 (225–318.7)

515.9 (426.9–609.4)

90%

4,130.9 (3,546.5–4,389.3)

3,011 (2,635.2–4,183.6)

−27%

  Hemorrhagic and other non-ischemic stroke

65.6 (54.3–77.7)

124.6 (102.1–147.8)

90%

2,306.5 (2,058.8–2,601.6)

1,741.8 (1,502.3–1,936)

−24%

  Hypertensive heart disease

28.3 (17.3–42.8)

46.5 (28.8–71.4)

65%

531.9 (432.3–671.4)

613 (490.4–764.1)

15%

  Cardiomyopathy and myocarditis

17.5 (10.3–27.4)

26.6 (16.3–40.9)

52%

537.7 (496.6–569.2)

723.9 (634–857.1)

35%

  Atrial fibrillation and flutter

278.3 (186.1–398)

460.9 (306.5–658)

66%

363.2 (269.6–484.1)

849.2 (631.8–1127.7)

134%

  Aortic aneurysm

0 (0–0)

0 (0–0)

–*

261.2 (199.7–339.1)

308.2 (224.6–403.1)

18%

  Peripheral vascular disease

39.5 (20.1–70.8)

60.7 (30.8–109.7)

54%

83.5 (54.6–124.9)

174.6 (116.3–253.8)

109%

  Endocarditis

4.2 (2.4–6.8)

7.4 (4.5–11.6)

75%

74.6 (64–86.9)

76.3 (59.9–88)

2%

  Other cardiovascular and circulatory diseases

343.8 (182.1–561.1)

508.7 (275.7–807.5)

48%

1,761.1 (1,592.8–1,992.2)

1,740.9 (1,496.8–2,046.5)

−1%

Chronic respiratory diseases

1,935.1 (1,247–2,764.6)

22,17.7 (14,39.4–31,23.6)

15%

5,623.2 (4,907.3–6,436.1)

5,260.3 (4,434.9–6,184.9)

−6%

  Chronic obstructive pulmonary disease

860.7 (5,23.1–1,276.8)

10,99.1 (683–15,94.7)

28%

3,030.1 (2,586.4–3,515.9)

2,916 (2,423.7–3,483.1)

−4%

  Pneumoconiosis

8.3 (5.3–12)

15.9 (10–23.7)

92%

195.7 (134.5–283)

158.8 (112.5–223.2)

−19%

  Asthma

749.4 (411.4–1,203.2)

791.4 (443–1,253.1)

6%

969.4 (632.4–1423.6)

917.8 (564.5–1377.3)

−5%

  Interstitial lung disease and pulmonary sarcoidosis

8.9 (5.9–13.3)

16.1 (10.4–24.3)

81%

158.8 (118.1–251.5)

262.6 (181.8–373)

65%

  Other chronic respiratory diseases

307.9 (187–458.9)

295.2 (183.7–431.1)

−4%

1,269.2 (988–1,483.8)

1,005.2 (819.7–1,264)

−21%

Cirrhosis of the liver

34.4 (21.9–49.6)

37.6 (24.3–54)

9%

2,358.1 (1,931.4–2,609.8)

1,772.7 (1585.9–2,231.2)

−25%

  Cirrhosis of the liver secondary to hepatitis B

1.3 (0.5–2.5)

1.3 (0.5–2.6)

4%

89.4 (70.2–105.5)

67.9 (57–86.1)

−24%

  Cirrhosis of the liver secondary to hepatitis C

13.2 (7.4–21.5)

14.4 (7.7–23.3)

9%

895 (711.6–1049.2)

687.1 (582–870.4)

−23%

  Cirrhosis of the liver secondary to alcohol use

15.8 (8.9–25)

17.5 (9.9–28.4)

11%

1,105.7 (847.2–1295.5)

830.5 (694.9–1,084.7)

−25%

  Other cirrhosis of the liver

4.1 (2–6.9)

4.3 (2.1–7.6)

4%

268 (211.1–313.4)

187.2 (156.9–238.2)

−30%

Digestive diseases (except cirrhosis)

423.2 (248.1–730.7)

492.4 (313.7–755.8)

16%

1,683 (1,452.6–2,012.8)

1,860 (1,610.1–2,164.5)

11%

  Peptic ulcer disease

34 (17.9–64.8)

21.8 (11–46.2)

−36%

251.8 (202.3–293.9)

116.2 (95–164.7)

−54%

  Gastritis and duodenitis

29.9 (19.3–44.6)

38.8 (25.8–56.3)

30%

46.9 (33.4–62.6)

46.5 (32.1–65)

−1%

  Appendicitis

7.8 (2.8–16.7)

8.3 (3–17.8)

6%

43.7 (30.9–65.7)

37.7 (22.8–52.5)

−14%  

  Paralytic ileus and intestinal obstruction without hernia

0.6 (0–2.7)

0.6 (0–2.6)

3%

123.3 (96.4–175.4)

169.4 (106.6–226.9)

37%

  Inguinal or femoral hernia

28.3 (6.6–84)

28.9 (5.7–81.8)

2%

55.8 (33.9–110.3)

48.7 (25.4–101.4)

−13%

  Non-infective inflammatory bowel disease

205.8 (88.9–434.4)

214.3 (109.5–390.4)

4%

243.3 (127.2–473.9)

257 (151.9–435.7)

6%

  Vascular disorders of intestine

1 (0.2–2.4)

1.6 (0.3–3.9)

70%

232.9 (117.1–468.5)

313.5 (166–604)

35%

  Gall bladder and bile duct disease

36.4 (24.5–51.6)

45.6 (30.7–64.3)

25%

189.2 (161.3–229.6)

207.8 (164.8–260.5)

10%

  Pancreatitis

16.3 (5.8–38.3)

37.2 (12.8–83.9)

128%

224.4 (164.8–275.8)

228.1 (177–303.9)

2%

  Other digestive diseases

63.2 (37–108.4)

95.3 (60.6–146.9)

51%

271.7 (228–356.4)

435.1 (337.6–529.1)

60%

Neurological disorders

3,407 (2,631.9–4,321.9)

4,627.9 (3,616.3–5,804.5)

36%

4,581 (3,789.1–5,481.9)

7,372.4 (6,127.5–8,666.4)

61%

  Alzheimer's disease and other dementias

858.3 (612.7–1,136)

1,640.7 (1,185–2,196.8)

91%

1,433.9 (1,138.4–1,754.3)

3,518 (,2707.8–4,334.5)

145%

  Parkinson's disease

71.8 (46–114.3)

115.7 (72.9–189)

61%

230.4 (180.8–300.8)

390 (290.8–496.1)

69%

  Epilepsy

292 (215.3–381.1)

324 (242.9–425.2)

11%

399.4 (320.1–491.9)

432.1 (343–538.1)

8%

  Multiple sclerosis

37.7 (26.5–51)

54.5 (37.3–74.1)

45%

82.1 (67.6–98.9)

109 (86.3–133.8)

33%

  Migraine

1,893.5 (1,198.1–2,731.1)

2,146 (1,339.7–3,101.9)

13%

1893.5 (1198.1–2731.1)

2146 (1339.7–3101.9)

13%

  Tension-type headache

117.1 (65.8–188)

144.1 (82.7–233.9)

23%

117.1 (65.8–188)

144.1 (82.7–233.9)

23%

  Other neurological disorders

136.7 (102.7–176.2)

202.8 (153.7–261.7)

48%

424.5 (336.1–567.1)

633.1 (480.2–802.4)

49%

Mental and behavioral disorders

10,177.2 (8,247.3–12,325.7)

12,464.1 (10,170.8–15,032.3)

22%

10,528.7 (8,600.5–12,716.4)

12,917.2 (10,630.6–15,432.4)

23%

  Schizophrenia

771.1 (443.1–1,144.3)

1,052.2 (583.9–1,591.4)

36%

781.6 (453.6–1,153.9)

1,074.7 (606.8–1,614.1)

37%

  Alcohol use disorders

691 (381.2–1156.4)

757.1 (401.2–1,235.8)

10%

797 (482.4–1,257.7)

882.1 (514.8–1,385.4)

11%

  Drug use disorders

1,644.7 (1,176.5–2,156.1)

1,784.5 (1,277.6–2,334.5)

9%

1,873.5 (1,391–2,416.5)

2,076 (1,536.1–2,677.5)

11%

  Opioid use disorders

746.5 (502.9–1003.1)

844.4 (571.9–1,134.8)

13%

886.9 (629.1–1,165.1)

1,016.2 (728.8–1,339.5)

15%

  Cocaine use disorders

195.6 (112.9–306.5)

216.7 (124.3–335)

11%

199.3 (117.2–313.6)

218.6 (124.8–338.9)

10%

  Amphetamine use disorders

155.2 (86.9–249.2)

162.1 (91.4–255.5)

4%

157.2 (88.8–251.8)

164.5 (92.3–262.9)

5%

  Cannabis use disorders

213.6 (107.1–377.3)

201.5 (100.3–367.1)

−6%

213.6 (107.1–377.3)

201.5 (100.3–367.1)

−6%

  Other drug use disorders

333.8 (205.6–499.4)

359.8 (226.7–523.5)

8%

416.4 (280.9–592.2)

475.1 (327–669.2)

14%

  Unipolar depressive disorders

4,011.1 (2,829.7–5,395.6)

5,308.1 (3,910.9–7,025.8)

32%

4,011.1 (2,829.7–5,395.6)

5,308.1 (3,910.9–7,025.8)

32%

  Major depressive disorder

3,352.4 (2,332.1–4,626.6)

4,521.8 (3,227.7–6,093.6)

35%

3,352.4 (2,332.1–4,626.6)

4,521.8 (3,227.7–6,093.6)

35%

  Dysthymia

658.7 (426.3–922.7)

786.3 (508.1–1,094.9)

19%

658.7 (426.3–922.7)

786.3 (508.1–1,094.9)

19%

  Bipolar affective disorder

696.1 (425.1–1051)

835.3 (510.6–1,251.2)

20%

696.1 (425.1–1051)

835.3 (510.6–1251.2)

20%

  Anxiety disorders

1,213.6 (826.9–1,673.9)

1331.1 (906.8–1,856.4)

10%

1,213.6 (826.9–1,673.9)

1,331.1 (906.8–1,856.4)

10%

  Eating disorders

296.4 (171.5–476.8)

570.1 (334.2–924.9)

92%

298.7 (174.6–479.3)

574.6 (339.7–929.5)

92%

  Pervasive development disorders

399.8 (269.4–578.2)

452.2 (302.8–648.9)

13%

399.8 (269.4–578.2)

452.2 (302.8–648.9)

13%

  Autism

188.8 (122.7–275.7)

216.3 (140.4–317.6)

15%

188.8 (122.7–275.7)

216.3 (140.4–317.6)

15%

  Asperger’s syndrome

211.1 (134.8–319.5)

235.8 (154.4–352.7)

12%

211.1 (134.8–319.5)

235.8 (154.4–352.7)

12%

  Childhood behavioral disorders

291.8 (171.3–450.9)

209.7 (120.2–323.4)

−28%

291.8 (171.3–450.9)

209.7 (120.2–323.4)

−28%

  Attention-deficit hyperactivity disorder

27 (15.2–43.6)

20.8 (11.8–33.8)

−23%

27 (15.2–43.6)

20.8 (11.8–33.8)

−23%

  Conduct disorder

264.7 (151–419.6)

188.9 (105–299.2)

−29%

264.7 (151–419.6)

188.9 (105–299.2)

−29%

  Idiopathic intellectual disability

92 (53.5–142.5)

74.1 (38–123.4)

−19%

92 (53.5–142.5)

74.1 (38–123.4)

−19%

  Other mental and behavioral disorders

69.5 (41–108.2)

89.7 (52–143.5)

29%

73.4 (44.8–112.2)

99.2 (60.1–152.2)

35%

Diabetes, urogenital, blood, and endocrine diseases

4,245.7 (3,050.2–5,693.7)

5,381.9 (3,956.8–7,145.9)

27%

7,013.4 (5,814.5–8,532.3)

8,414.8 (6,968.8–1,0395.6)

20%

  Diabetes mellitus

2,207.8 (1461.1–3173)

2,807.9 (1,906.5–4,022.5)

27%

3,490.7 (2,731.4–4,487.2)

3,954.2 (3,014.9–5,187.7)

13%

  Acute glomerulonephritis

0 (0–0.1)

0 (0–0)

−9%

3.8 (2.4–6.7)

2.5 (1.1–3.9)

−34%

  Chronic kidney diseases

537.1 (370.6–805.8)

770.3 (538.4–1101)

43%

1,371.7 (1,146.5–1,649.9)

1,590.2 (1,313.1–1,967.6)

16%

  Chronic kidney disease due to diabetes mellitus

80.8 (52.9–117.2)

119.3 (78.1–172.1)

48%

214.8 (173.7–261.2)

242 (190.6–308.7)

13%

  Chronic kidney disease due to hypertension

99.2 (66.2–147.1)

143.9 (97.4–204.3)

45%

264.7 (219.2–322.4)

315.3 (257.2–393.6)

19%

  Chronic kidney disease unspecified

357.1 (240.4–547.6)

507.1 (352.2–735)

42%

892.2 (740.5–1101.4)

1,032.9 (841.5–1,303.6)

16%

  Urinary diseases and male infertility

395.5 (254.4–603.1)

541.2 (347.1–812.7)

37%

604.2 (451.8–809.5)

963.5 (717.5–1,265.4)

59%

  Tubulointerstitial nephritis, pyelonephritis, and urinary tract infections

5.9 (2.6–11.2)

7.4 (3.5–14.3)

27%

156.5 (124.4–229.1)

328.8 (177.1–474.9)

110%

  Urolithiasis

50 (27.3–81.3)

72.6 (40.1–114.7)

45%

59.1 (36–91.8)

78.8 (46.4–122.1)

33%

  Benign prostatic hyperplasia

319.6 (201.5–487.1)

431.8 (270.1–654.1)

35%

319.6 (201.5–487.1)

431.8 (270.1–654.1)

35%

  Male infertility

3.2 (1.2–7.1)

4.2 (1.6–9)

32%

3.2 (1.2–7.1)

4.2 (1.6–9)

32%

  Other urinary diseases

16.9 (9.5–27.4)

25.1 (14.1–40.3)

49%

65.9 (51.6–86)

119.8 (87.9–155.5)

82%

  Gynecological diseases

464.2 (258.8–797)

585.2 (325.2–999)

26%

468.9 (263.7–801.4)

590.4 (330–1,004)

26%

  Uterine fibroids

96.8 (43.5–190.7)

139.2 (60.2–268.9)

44%

97.2 (43.9–191.1)

139.7 (60.8–269.4)

44%

  Polycystic ovarian syndrome

142.4 (66.4–265.2)

170.3 (77.9–324.2)

20%

142.4 (66.4–265.2)

170.3 (77.9–324.2)

20%

  Female infertility

2.5 (0.9–5.4)

3.1 (1.1–6.7)

24%

2.5 (0.9–5.4)

3.1 (1.1–6.7)

24%

  Endometriosis

27.1 (9–52.7)

34.3 (12.4–66.5)

27%

27.1 (9–52.7)

34.3 (12.4–66.5)

27%

  Genital prolapse

123.8 (49.5–259.5)

156.3 (62.6–339.3)

26%

124.2 (49.9–259.9)

156.7 (63–339.7)

26%

  Premenstrual syndrome

71.7 (0–200.2)

82.1 (0–213.6)

14%

71.7 (0–200.2)

82.1 (0–213.6)

14%

  Other gynecological diseases

0 (0–0)

0 (0–0)

–*

3.9 (3.4–4.6)

4.2 (3.3–5.4)

10%

  Hemoglobinopathies and hemolytic anemia

498.7 (296.2–1080.4)

477.4 (291.8–935)

−4%

599.4 (393.7–1,169.3)

540.7 (350.5–997.4)

−10%

  Thalassemia

161.4 (102.1–247.1)

156.1 (99.3–254.6)

−3%

174.9 (115.5–260.7)

162.3 (105.8–260.9)

−7%

  Sickle cell disorders

309.9 (171.6–832.4)

296.2 (172.1–703.8)

−4%

338.4 (199.5–859.6)

309.3 (184.8–715.3)

−9%

  G6PD deficiency

24.8 (11.7–93.6)

18.3 (9.3–58.9)

−26%

32.5 (19–101.1)

22.5 (13.2–62.6)

−31%

  Other hemoglobinopathies and hemolytic anemia

2.5 (0.5–1.8)

6.7 (0.9–9.3)

169%

53.6 (36.2–64.7)

46.6 (31.4–79.2)

−13%

  Other endocrine, nutritional, blood, and immune disorders

142.4 (83.1–228.4)

199.8 (115.9–362)

40%

474.8 (329.2–710.6)

773.4 (529.7–1,539.3)

63%

Musculoskeletal disorders

11,220.4 (,8585.2–14,277.6)

14,278.5 (10,905.8–17,775.5)

27%

11,469.4 (88,29.8–14,558.2)

14,654.1 (11,291.8–18,160.2)

28%

  Rheumatoid arthritis

477.5 (345.2–636.5)

665.5 (465.5–881)

39%

519.4 (384.9–684.3)

710.1 (509.5–925.6)

37%

  Osteoarthritis

1,055.3 (648.4–1,604.3)

1,407.1 (877.8–2,066.2)

33%

1,055.3 (648.4–1,604.3)

1,407.1 (877.8–2,066.2)

33%

  Low back and neck pain

7,363.4 (5,148.2–9,886.3)

9,178.1 (6,357.5–12,295.1)

25%

7,363.4 (5,148.2–9,886.3)

9,178.1 (6,357.5–1,2295.1)

25%

  Low back pain

4,784.5 (3,305.8–6,484.6)

6,011.7 (4,104.5–8,080.9)

26%

4,784.5 (3,305.8–6,484.6)

6,011.7 (4,104.5–8,080.9)

26%

  Neck pain

2,578.9 (1,769.5–3,608.8)

3,166.3 (2,193.9–4,438)

23%

2,578.9 (1,769.5–3,608.8)

3,166.3 (2,193.9–4,438)

23%

  Gout

21.6 (13.4–32.1)

30.2 (19–45.1)

40%

21.6 (13.4–32.1)

30.2 (19–45.1)

40%

  Other musculoskeletal disorders

2,302.7 (1,585.5–3,228.6)

2,997.7 (2,089.4–4,136.6)

30%

2,509.7 (1,803.7–3,433.4)

3,328.7 (2,440.8–4,471.4)

33%

Other non-communicable diseases

4,700.2 (3,172.4–6,899.1)

5,087.8 (3,400.3–7,616.6)

8%

6,009.2 (4,467.8–8,218.2)

5,881.5 (4,184.3–8,375.2)

−2%

  Congenital anomalies

130.9 (93.7–182.5)

141 (101.2–201.8)

8%

1,278.3 (1,065.6–1,416.6)

778.7 (685.8–973.5)

−39%

  Neural tube defects

11.6 (6.4–18.7)

8.2 (4.4–13.6)

−29%

99.4 (58.5–126.5)

18.5 (12.5–28)

−81%

  Congenital heart anomalies

34.2 (17.6–66.8)

32.4 (15.9–67.4)

−5%

566.6 (460.8–650.2)

321.4 (254.9–411.9)

−43%

  Cleft lip and cleft palate

5.4 (2.7–9.7)

6 (3.1–10.5)

12%

7.9 (4.9–12.4)

7.4 (4.3–12.1)

−6%

  Down’s syndrome

38.1 (21.6–61.4)

46.5 (27.1–74.6)

22%

104 (69.3–138.5)

104.7 (80.1–136)

1%

  Other chromosomal abnormalities

14.5 (8–23.9)

17.4 (10.1–29.2)

19%

59.4 (41.1–78.5)

55 (39.2–77.1)

−7%

  Other congenital anomalies

27.1 (19.1–38.3)

30.6 (21.8–44.9)

13%

441 (294.4–539.7)

271.6 (215.5–397.8)

−38%

  Skin and subcutaneous diseases

1,989.9 (1,235.6–3,086)

2,206.8 (1,347–3,476.9)

11%

2,058.2 (1,302–3,150.8)

2,301.8 (1,445–3,558.5)

12%

  Eczema

462.2 (233.8–802)

511.7 (252.5–845.6)

11%

462.2 (233.8–802)

511.7 (252.5–845.6)

11%

  Psoriasis

87.3 (42.4–145.8)

105.1 (50–172.9)

20%

87.3 (42.4–145.8)

105.1 (50–172.9)

20%

  Cellulitis

11.1 (1.2–45.6)

11 (1.3–45.3)

−1%

26.2 (15.7–60.2)

29.6 (16.9–63.8)

13%

  Abscess, impetigo, and other bacterial skin diseases

41.8 (16.9–85.1)

49.3 (19.8–101.3)

18%

63.3 (38–107.4)

76 (45.7–129.6)

20%

  Scabies

22.9 (10.1–44.9)

26.2 (11.8–49)

15%

22.9 (10.1–44.9)

26.2 (11.8–49)

15%

  Fungal skin diseases

107.6 (33.8–246.6)

128.2 (39.3–291.8)

19%

107.6 (33.8–246.6)

128.2 (39.3–291.8)

19%

  Viral skin diseases

189.2 (72.5–359.4)

182.5 (66.3–336.4)

−4%

189.2 (72.5–359.4)

182.5 (66.3–336.4)

−4%

  Acne vulgaris

312.6 (139.6–589.8)

237.6 (106.6–469.3)

−24%

312.6 (139.6–589.8)

237.6 (106.6–469.3)

−24%

  Alopecia areata

78.7 (23–158.4)

91.1 (25.1–182.4)

16%

78.7 (23–158.4)

91.1 (25.1–182.4)

16%

  Pruritus

179.4 (82.5–347.4)

244.2 (110.2–489.4)

36%

179.4 (82.5–347.4)

244.2 (110.2–489.4)

36%

  Urticaria

137.4 (55.3–236.9)

159 (65–271)

16%

137.4 (55.3–236.9)

159 (65–271)

16%

  Decubitus ulcer

30 (9.8–69.2)

40.3 (12.9–96.9)

34%

61.5 (39.8–101.6)

89.7 (55–150.1)

46%

  Other skin and subcutaneous diseases

329.6 (155.1–610.6)

420.8 (193.8–806.2)

28%

329.8 (155.2–610.6)

421 (193.9–806.3)

28%

Sense organ diseases

1637 (1164–2335)

1,850.2 (1291.1–2,656.9)

13%

1,637 (1,164–2,335)

1,850.2 (1,291.1–2,656.9)

13%

  Glaucoma

36 (23–54.9)

56.9 (37.6–82.7)

58%

36 (23–54.9)

56.9 (37.6–82.7)

58%

  Cataracts

193.1 (136.8–261.7)

170.7 (116.3–233.8)

−12%

193.1 (136.8–261.7)

170.7 (116.3–233.8)

−12%

  Macular degeneration

58.4 (37.5–87.3)

107.8 (71.8–152.9)

85%

58.4 (37.5–87.3)

107.8 (71.8–152.9)

85%

  Refraction and accommodation disorders

84 (61.3–110.7)

107.9 (77.6–142.3)

28%

84 (61.3–110.7)

107.9 (77.6–142.3)

28%

  Other hearing loss

926.8 (541.4–1480.3)

962.7 (554.5–1598.5)

4%

926.8 (541.4–1,480.3)

962.7 (554.5–1,598.5)

4%

  Other vision loss

329.9 (174.9–586)

433.2 (222–771)

31%

329.9 (174.9–586)

433.2 (222–771)

31%

  Other sense organ diseases

8.8 (3–19.8)

11 (3.7–25.4)

25%

8.8 (3–19.8)

11 (3.7–25.4)

25%

Oral disorders

942.4 (564.3–1507.7)

889.8 (519.4–1403.9)

−6%

942.4 (564.3–1,507.7)

889.8 (519.4–1,403.9)

−6%

Dental caries

110.2 (45–216.1)

130.4 (52.8–250.1)

18%

110.2 (45–216.1)

130.4 (52.8–250.1)

18%

Periodontal disease

143 (54.8–312.3)

193.8 (72.6–400.1)

36%

143 (54.8–312.3)

193.8 (72.6–400.1)

36%

Edentulism

689.2 (394.8–1103.5)

565.6 (322–903)

−18%

689.2 (394.8–1103.5)

565.6 (322–903)

−18%

Sudden infant death syndrome

0 (0–0)

0 (0–0)

–*

93.3 (40.6–150.8)

61 (31.4–111.4)

−35%

Injuries

3,873.3 (2,679.9–5,500.9)

5,495 (3,846.6–7,727.1)

42%

11,961.1 (10,559.1–13,749.9)

9,962.5 (8,154–12,170.7)

−17%

Transport injuries

1,134 (763.2–1,670.3)

1,428.6 (975–2,074.9)

26%

4,925.5 (4,315.5–5,683.5)

3,047.6 (2,494.2–3,809.3)

−38%

  Road injury

982.9 (659–1,450.2)

1,197.1 (810.2–1,745.7)

22%

4,671.5 (4,049.7–5,342.3)

2,692.9 (2,226.1–3,328.1)

−42%

  Pedestrian injury by road vehicle

169 (113.6–248.3)

243.2 (165–350.8)

44%

580.3 (487.4–761.5)

464.4 (372.3–584.4)

−20%

  Pedal cycle vehicle

18.8 (12.7–27.8)

50.5 (34.2–74.1)

169%

71.2 (53.8–110.9)

107.2 (75.3–136.5)

51%

  Motorized vehicle with two wheels

232.4 (155.6–347.3)

172.6 (116.1–252.7)

−26%

1,423.3 (1,009.6–1,638.8)

436 (360.3–539.5)

−69%

  Motorized vehicle with three or more wheels

576.6 (386.6–852.7)

779.7 (527.3–1134.8)

35%

2,579.1 (2,156.9–3,157.2)

1,722.1 (1,368.2–2,279.8)

−33%

  Road injury other

13 (8.8–19.2)

12.1 (8.2–17.4)

−7%

44.6 (31.7–60)

24 (17.7–33.7)

−46%

  Other transport injury

151.1 (102.4–223)

231.5 (157.9–331.2)

53%

254 (189.8–359.6)

354.8 (275.4–460.4)

40%

Unintentional injuries other than transport injuries

2,638 (1,821–3,727.8)

3,944 (2,760.5–5,515.8)

50%

5,486.5 (4,503.8–6,659)

5,472.7 (4,205.3–7,082.7)

0%

  Falls

2,150.2 (1,471.2–3043.3)

3,315.8 (2,316.6–4,644.3)

54%

2,462.8 (1,754.8–3,385.5)

3,763.4 (2,726.7–5,125)

53%

  Drowning

9.7 (6.1–14.5)

11.1 (7–16.8)

14%

404.4 (312.7–497.3)

222.8 (181–295.5)

−45%

  Fire, heat and hot substances

57 (30.5–106.3)

70.2 (37.6–127.1)

23%

158.1 (122.4–213)

141 (105.1–202.2)

−11%

  Poisonings

9.2 (5.6–14.6)

7.1 (4.3–11.3)

−23%

220.6 (153.6–338.5)

165.9 (79.7–233.9)

−25%

  Exposure to mechanical forces

72.6 (45.5–114)

75.2 (47.8–113.9)

4%

269.1 (212.6–366.4)

185.4 (130.8–252.4)

−31%

  Mechanical forces (firearm)

26.9 (17–42.2)

14.6 (9.4–22.2)

−46%

94.8 (56.5–123)

31.6 (22.7–47.7)

−67%

  Mechanical forces (other)

56.5 (35.4–88.2)

79.1 (50.2–119.5)

40%

185.1 (147.6–282.1)

172.3 (131.7–241.7)

−7%

  Adverse effects of medical treatment

45.3 (29.2–68.3)

102.6 (66–151.3)

127%

143.5 (115.6–181.7)

227.3 (174.5–307.9)

58%

  Animal contact

21.9 (14.2–32.8)

11.7 (7.7–17.2)

−47%

35.3 (26.2–47.7)

18.6 (14–25.1)

−47%

  Animal contact (venomous)

14.3 (8.7–22.3)

6.8 (4.3–10.5)

−53%

16.4 (10.6–24.8)

8.3 (5.6–12.2)

−50%

  Animal contact (non-venomous)

7.6 (4.8–11.8)

4.9 (3–7.3)

−36%

18.9 (13.9–24.7)

10.3 (7.8–13.9)

−45%

  Unintentional injuries not classified elsewhere

272.1 (185.1–396.4)

350.3 (232.7–505.7)

29%

1,792.7 (1,054.8–2,031)

748.2 (605.7–955.4)

−58%

Self-harm and interpersonal violence

101.3 (66.6–146.4)

122.3 (81.1–173)

21%

1,549.1 (1,277.2–2,016.4)

1,442.2 (1,051.7–1,690.9)

−7%

  Self-harm

12.6 (7.9–18.3)

15.2 (9.7–23.1)

21%

1,244.6 (9,62.4–1,686.8)

1,154.4 (7,59.7–1,377.5)

−7%

  Interpersonal violence

88.7 (58.4–129.4)

107.1 (70.8–151.4)

21%

304.5 (241.9–403)

287.8 (230.5–369.8)

−5%

  Assault by firearm

23.2 (15–34.3)

30.1 (19.5–42.9)

30%

74.6 (59–105.3)

74.2 (57.3–98.9)

−1%

Assault by sharp object

31.9 (20.9–46.9)

56.2 (37–79.6)

76%

106.7 (79.1–175.7)

143.2 (94.8–186.6)

34%

  Assault by other means

40.1 (26.5–57.7)

31.3 (21–43.8)

−22%

129.7 (98.4–158.1)

80.9 (65.5–106)

−38%

Data are presented as mean values and uncertainty intervals (Lower, Upper).

*– not applicable.

Putting premature mortality and disability together in terms of DALYs provides an overall picture of the leading health problems in Spain. Between 1990 and 2010, there was a slight increase (5.4%) in DALYs (i.e., overall health burden) in the overall Spanish population (from 104,615.9 in 1990 to 110,269.4 in 2010). The dominant causes of DALYs in 2010 were neoplasms, cardiovascular and circulatory diseases, musculoskeletal disorders, mental and behavioral disorders, and diabetes, urogenital, blood, and endocrine diseases, which accounted for nearly 59% of all DALYs (Table 3).

The top five leading causes for DALYs remained similar in both 1990 and 2010, despite the decreases or increases in the number of DALYs for each cause (% of change between the numbers of DALYs). There was only a slight change in numerical order between the first two causes. Due to a large decrease in the number of DALYs (11%), cardiovascular and circulatory diseases dropped to the second cause of DALYs in 2010 and neoplasms reached the first position increasing by 14% from 1990. Between the sixth and the eleventh positions the causes for DALYs changed only slightly. The transport injuries dropped from the ninth position in 1990s to the tenth in 2010, due to a large decrease (38%) in the number of DALYs. The neurological disorders, with a 61% increase in DALYs, achieved the sixth position in 2010 from its tenth position in 1990. The HIV/AIDS and tuberculosis cause dropped one position and neonatal disorders increased one position in the list of causes for DALYs for the year 2010. Finally, the last four causes among the 20 top ranking of DALYs in Spain remained completely stable between 1990 and 2010, despite the changes in disability (Figure 3).
Figure 3

Spanish disability-adjusted life years (DALYs) ranks for the top 20 main causes in 1990 and 2010, and the percentage change between 1990 and 2010. Continuous line represents an ascending order in rank and the broken line represents a descending order. (Δ%) = % of change in absolute numbers of DALYs.

Summarizing the above data, in 2010, the leading causes for DALYs among newborn children (0–1 years old) were neonatal disorders and the other communicable diseases group. The leading causes for DALYs in the younger group (5 to 44 years old) in the Spanish population were mental and behavioral disorders and musculoskeletal disorders, while in the middle aged and older adults groups the leading causes shifted to cardiovascular and circulatory diseases and neoplasms (Figure 4).
Figure 4

DALYs in Spain by cause and age in 2010. Adopted and modified from GBD data visualizations.

In both 1990 and 2010, there was a high consistency across European countries regarding the top causes of YLDs being major depressive disorders, musculoskeletal disorders, low back and neck pain, and diabetes, as well as injuries (i.e., falls). YLDs caused by asthma, anxiety disorders, and chronic obstructive pulmonary disease ranked lower in Spain compared with other southern European countries, in both 1990 and 2010 (Figure 5).
Figure 5

Age-standardized YLDs ranking relative to comparator European countries by the top 20 causes in (A) 1990 and (B) 2010. Numbers in cells indicate the ranks by country for each cause, with 1 being the disorder with the highest impact. The presented causes are ordered by the 20 leading causes of YLDs in Spain. YLDs, Years lived with disability; COPD, Chronic obstructive pulmonary disease. Adopted and modified from GBD data visualizations.

From 1990 to 2010 overall DALYs attributable to non-communicable diseases in Spain increased by 897,900 from 8,626,000 to 9,523,900. When standardizing the DALYs of 2010 to the 1990 population, the number of DALYs which would have increased was estimated to be 1,250,900. Thus, the actual population health improved since the demographic changes would have caused a higher increase in DALYs than the actual 2010 DALYs. Changes in DALYs mostly correspond to population increase and are secondary to population ageing. Moreover, the highest difference was attributed to those 40 years and older.

Discussion

During the past 20 years, substantial changes have taken place in the relative impact of burden of diseases in Spain: while musculoskeletal disorders have increased by 28% (rank 3 as major cause of DALYs), mental and behavioral disorders have increased by 23% (rank 4), neurological disorders by 61% (rank 6), and neoplasms by 14% (rank 1). On the other hand, cardiovascular and circulatory diseases have decreased by 11% (now rank 2), transport injuries by 38% (rank 10), and chronic respiratory diseases by 6% (rank 9). Despite the population growth of 15% between 1990 and 2010 and the ageing of the population, the burden of disease increased only by 5%. The analysis of changes by age and gender group denoted that DALYs decreased when analyzed as rates per 100,000 population.

The relevance of neoplasms and cardiovascular and circulatory diseases on population health is mostly driven by mortality. Accordingly, the cardiovascular and circulatory diseases, neoplasms, and injuries due to transport reasons were the top three leading causes for the burden of YLLs. However, the impact of musculoskeletal disorders and mental disorders is mostly through YLDs, since they are the first and second causes in the ranking. Together, these two groups of disorders, accounted for almost the half (48%) of all YLDs in Spain. Additionally, depression, and other mental disorders (like anxiety, etc.) have been associated to various musculoskeletal disorders [17],[18]. All these conditions are related to occupational risk, particularly low back pain [19], and absenteeism. The impact of these disorders and the need for mental health promotion and musculoskeletal health prevention may have been underestimated by public health authorities and policies [20].

Other studies have previously evaluated the burden of morbidity and mortality in Spain [8],[9]. According to these, in 2008, the major causes for mortality in males and females were also cardiovascular diseases and malignant neoplasms [8]. Furthermore, a recent study in Valencia reported similar results in mortality rates in the local population (i.e., 26% of all deaths due to malignant tumors and 34% due to cardiovascular diseases [9]).

Clear gender differences emerged in the analyses. Specifically, in males, cancer (i.e., neoplasms) was the main mortality cause followed by cardiovascular diseases, while in females the order was reversed. Risk factor differences may be causing the increased impact of cancer in males: they still have higher rates of smoking and heavy alcohol consumption [21],[22]. The increased mortality of cardiovascular diseases in females is due to cerebro-vascular problems. Further, hormonal factors (disappearance of the protective role of estrogens after menopause) have been associated to the increased risk of stroke in females [23].

The top five causes for the burden of YLDs in Spain are similar to those in the other Mediterranean countries (except for slight differences with France) [24]-[26]. Similar results appeared also in the burden of DALYs comparing Spain to other European countries [24]-[26]. These similarities in the Mediterranean population’s health could be a result of the common lifestyle habits (dietary habits, smoking, physical activity, etc.) [27], as well as shared genetic traits within the region [28]. Spain, as well as other Mediterranean countries, has to shift the provided health care services from curative to preventive [29],[30] and to identify the priority diseases for health research funding and prevention policies development [8].

When comparing the results among all European countries, some remarkable results have also been found. While there are substantial differences in the rank order of diseases regarding DALY’s [7], there are much less differences in the first five causes of YLDs across European countries. Country differences may be mostly caused by differences in mortality instead of differences in YLDs. Whether this can be attributed to mortality figures being recorded more systematically in each country than prevalence figures should still be clarified.

In 2010, Spain presented the same leading conditions for YLLs compared to other Mediterranean countries, such as Greece, France, and Italy [24]-[26]. In 2010, Spain, France, and Italy showed age-standardized YLL rates for liver cancers significantly higher than the overall mean rate. Spain and Greece showed significantly higher rates of age-standardized YLL rates for bladder cancers [7]. Besides, the leading causes for premature mortality in the UK seem to be similar with those in Spain (i.e., cardiovascular and circulatory diseases and trachea, bronchus, and lung cancers [24]-[26]).

Globally, there is continuous shift from communicable to non-communicable diseases as the leading causes of mortality and DALYs [2],[5]. According to the latest data for 2010, in the top ten leading causes of population’s mortality, five were classified as non-communicable [2]. Global DALYs remained stable from 1990 to 2010 [5]. However, the global age-standardized DALY rates [5] actually decreased, which is consistent with our findings in Spain. Ischemic heart disease was the leading cause of DALYs worldwide in 2010, followed by lower respiratory infections, stroke, diarrheal diseases, and HIV/AIDS. Depressive disorders, also climbed from the fifteenth to the eleventh rank and road injury from twelfth to tenth rank [2],[5]. However, in Spain the major causes for DALYs were neoplasms followed by cardiovascular diseases, musculoskeletal disorders, and mental disorders. Neurological disorders moved from the tenth to sixth rank; this high ranking in musculoskeletal disorders was quite similar with the global estimates [5] – low back pain and neck pain are the most important contributors accompanied by osteoarthritis, rheumatoid arthritis, and gout [5],[31]. The pathophysiology of chronic diseases, especially cardiovascular diseases and cancers, is complex, with the interaction of new environmental risk factors (e.g., multimorbidity, financial status, etc.), in addition to the classical modifiable risk factors (i.e., cognition reserve, smoking, unhealthy diet, physical activity, hypertension, etc.), making the prevention of chronic diseases in older adults quite difficult. Efforts to improve and protect health, prevent disease and injury, and deliver high-quality health care to the population must be tailored to address the causes associated with the greatest burden mainly of chronic diseases [32]. It is expected that preventive strategies can influence many of the aforementioned chronic conditions and non-communicable causes and increase the quality of life, while averting or minimizing the need for expensive medical care [33],[34]. Furthermore, the engagement with the GBD collaborative group will provide more and better analysis data of the global burden of disease and, specifically, in Spain – a fact that will contribute to continuous improvements of the health estimates in future iterations of the GBD study.

Limitations

The previous results should be considered taking into account the following limitations. Although Spain follows the European Statistics Code of Practice of 2006–2008 and data is collected in a consistent way across the country, there are a number of issues that should be considered when analyzing the results. Regarding mortality, the GBD project defined a number of garbage codes, which are causes of death that should not be identified as underlying causes of death but have been entered as the underlying causes of death on death certificates. Garbage codes were substituted by underlying causes based on pathophysiology. The fraction of garbage codes in Spain was within the world average. The substitution of garbage codes has impact on mortality causes. For example, in 2010, transport injury deaths based on raw data from Spain were 2,257. After correction for garbage codes and other adjustments, this number increased to 3,657 deaths. Following the modeling process, it further increased to 3,950.

In this study, the calculation of DWs were based on surveys including several countries, and not just Spain. However, according to recent results [10], the DW assessments appeared to be consistent even among different cultural environments. Another aspect is the prevalence of the referred health conditions, which was based on epidemiological studies, a fact that may create uncertainty depending on the quality of the primary data. To overcome this issue, some expert groups developed tools to assess the risk of bias in the selected studies and sensitivity analyses were performed to weight study sizes according to their quality, or even to eliminate them from the final analysis [10]. As referred in previous works of the GBD study [10], Bayesian statistical models were used to estimate prevalence of conditions in each country by age, sex, and year. The nature of this estimation process implies that, in some cases, depending on the covariates, estimated variance might be smaller than the real variance across countries in a region, and in some other cases, uncertainty intervals for a specific estimate might be exaggerated. Furthermore, the calculation of uncertainty intervals throughout the Bayesian model analysis has provided some information on the extent of available information for Spain. However, the nature of the estimation process for causes of death and the prevalence of sequelae more generally lead to exaggerated uncertainty intervals in a high-income country such as Spain [12]. These wide uncertainty intervals may limit the number of the detected significant changes in the burden of disease between 1990 and 2010.

Conclusions

The present findings, together with previous work [5], suggest that cardiovascular and circulatory diseases, neoplasms, and mental and neurological disorders seem to be the leading causes of mortality as well as for YLDs and DALYs in Spain. Although several health promotion action plans have taken place globally [35],[36] in the past few years, morbidity throughout non-communicable diseases is increasing at alarming rates. Public health care systems have to focus further on the quality of health care services [37]. Furthermore, health promotion strategies should focus on health education programs that could improve quality of life. Public health care services have to shift from being curative to being preventive; in Spain, a strong emphasis should be given on health promotion, disease prevention, and rehabilitation.

Abbreviations

DALYs: 

Disability-adjusted life years

DW: 

Disability weight

GBD: 

Global Burden of Diseases, Injuries, and Risk Factors

UK: 

United Kingdom

YLDs: 

years lived with disability

YLLs: 

Years of life lost

Declarations

Acknowledgements

Dr. Stefano Tyrovolas received a scholarship from the Foundation for Education and European Culture (IPEP) for his postdoctoral research, of which this work is part. Dr. Lidia Sanchez-Riera received a research grant from Sociedad Española de Reumatología. Noe Garin is grateful to the FPU doctoral program (reference FPU12/05661) supported by the Spanish Ministry of Education, Culture and Sport.

Source of funding

Funding for GBD 2010 study was provided by the Bill & Melinda Gates Foundation. This research was done as part of GBD 2010 study. All authors declare that they have no other funding, or any other support that could inappropriately influence the presented work.

Authors’ Affiliations

(1)
Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Fundació Sant Joan de Déu. Dr Antoni Pujades
(2)
Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM
(3)
Unitat de Reumatologia. Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona
(4)
Instituto de Salud Musculoesquelética (InMusc), Calle Hilarión
(5)
Institute of Bone and Joint Research, Royal North Shore Hospital, University of Sydney, Pacific Hwy
(6)
Institut d’Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, Freixa Llarga s/n, 08907 L’Hospitalet de Llobregat
(7)
Rheumatology Division, Cruces University Hospital, Crystal-induced arthritis investigation team, BioCruces Health Investigation Institute
(8)
Institute for Health Metrics and Evaluation, University of Washington

References

  1. Murray CJ, Salomon JA, Mathers CD, Lopez AD: Summary Measures of Population Health: Concepts, Ethics, Measurement and Applications. 2002, WHO, GenevaGoogle Scholar
  2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012, 380: 2095-2128. 10.1016/S0140-6736(12)61728-0.View ArticlePubMedGoogle Scholar
  3. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997, 349: 1269-1276. 10.1016/S0140-6736(96)07493-4.View ArticlePubMedGoogle Scholar
  4. Bank W, World Development Report 1993: Investing in Health. 1993, Oxford University Press, New YorkGoogle Scholar
  5. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, et al: Disability-adjusted life years (DALYs)for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012, 380: 2197-2223. 10.1016/S0140-6736(12)61689-4.View ArticlePubMedGoogle Scholar
  6. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, Naghavi M, Salomon JA, Shibuya K, Vos T, Wikler D, Lopez AD: GBD 2010: design, definitions, and metrics. Lancet. 2012, 380: 2063-2066. 10.1016/S0140-6736(12)61899-6.View ArticlePubMedGoogle Scholar
  7. Murray CJ, Richards MA, Newton JN, Fenton KA, Anderson HR, Atkinson C, Bennett D, Bernabé E, Blencowe H, Bourne R, Braithwaite T, Brayne C, Bruce NG, Brugha TS, Burney P, Dherani M, Dolk H, Edmond K, Ezzati M, Flaxman AD, Fleming TD, Freedman G, Gunnell D, Hay RJ, Hutchings SJ, Ohno SL, Lozano R, Lyons RA, Marcenes W, Naghavi M, et al: UK health performance: findings of the global burden of disease study 2010. Lancet. 2013, 381: 997-1020. 10.1016/S0140-6736(13)60355-4.View ArticlePubMedGoogle Scholar
  8. Gènova-Maleras R, Álvarez-Martín E, Morant-Ginestar C, Fernández de Larrea-Baz N, Catalá-López F: Measuring the burden of disease and injury in Spain using disability-adjusted life years: an updated and policy-oriented overview. Public Health. 2012, 126: 1024-1031. 10.1016/j.puhe.2012.08.012.View ArticlePubMedGoogle Scholar
  9. Catalá-López F, Gènova-Maleras R, Ridao M, Alvarez E, Sanfélix-Gimeno G, Morant C, Peiró S: Burden of disease assessment with summary measures of population health for the Region of Valencia, Spain: a population-based study. Med Clin (Barc). 2013, 140: 343-350. 10.1016/j.medcli.2012.01.028.View ArticleGoogle Scholar
  10. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, et al: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012, 380: 2163-2196. 10.1016/S0140-6736(12)61729-2.View ArticlePubMedGoogle Scholar
  11. Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, Levin-Rector A, Levitz CE, Lopez AD, Murray CJ: Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012, 380: 2071-2094. 10.1016/S0140-6736(12)61719-X.View ArticlePubMedGoogle Scholar
  12. Granados JA: Health at advanced age: social inequality and other factors potentially impacting longevity in nine high-income countries. Maturitas. 2013, 74: 137-147. 10.1016/j.maturitas.2012.11.013.View ArticlePubMedGoogle Scholar
  13. Ahern RM, Lozano R, Naghavi M, Foreman K, Gakidou E, Murray CJ: Improving the public health utility of global cardiovascular mortality data: the rise of ischemic heart disease. Popul Health Metr. 2011, 9: 8-10.1186/1478-7954-9-8.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Mathers CD, Vos ET, Stevenson CE, Begg SJ: The burden of disease and injury in Australia. Bull World Health Organ. 2001, 79: 1076-1084.PubMedPubMed CentralGoogle Scholar
  15. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin Abdulhak A, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, et al: Common values in assessing health outcomes from disease and injury: disability weights measurement study forthe Global Burden of Disease Study 2010. Lancet. 2012, 380: 2129-2143. 10.1016/S0140-6736(12)61680-8.View ArticlePubMedGoogle Scholar
  16. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M: Age Standardization of Rates: A New WHO Standard; 2001. [http://www.who.int/healthinfo/paper31.pdf]
  17. Linton SJ: A review of psychological risk factors in back and neck pain. Spine. 2000, 25: 1148-1156. 10.1097/00007632-200005010-00017.View ArticlePubMedGoogle Scholar
  18. Antonopoulou MD, Alegakis AK, Hadjipavlou AG, Lionis CD: Studying the association between musculoskeletal disorders, quality of life and mental health. A primary care pilot study in rural Crete, Greece. BMC Musculoskelet Disord. 2009, 10: 143-10.1186/1471-2474-10-143.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Driscoll T, Jacklyn G, Orchard J, Passmore E, Vos T, Freedman G, Lim S, Punnett L: The global burden of occupationally related low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014, 73: 975-981. 10.1136/annrheumdis-2013-204631.View ArticlePubMedGoogle Scholar
  20. Min JA, Lee CU, Lee C: Mental health promotion and illness prevention: a challenge for psychiatrists. Psychiatry Investig. 2013, 10: 307-316. 10.4306/pi.2013.10.4.307.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Mashberg A, Boffetta P, Winkelman R, Garfinkel L: Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer. 1993, 72: 1369-1375. 10.1002/1097-0142(19930815)72:4<1369::AID-CNCR2820720436>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
  22. Rota M, Pasquali E, Bellocco R, Bagnardi V, Scotti L, Islami F, Negri E, Boffetta P, Pelucchi C, Corrao G, La Vecchia C: Alcohol drinking and cutaneous melanoma risk: a systematic review and dose-risk meta-analysis. Br J Dermatol. 2014, 170: 1021-1108. 10.1111/bjd.12856.View ArticlePubMedGoogle Scholar
  23. Haast RA, Gustafson DR, Kiliaan AJ: Sex differences in stroke. J Cereb Blood Flow Metab. 2012, 32: 2100-2107. 10.1038/jcbfm.2012.141.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Institute for Health Metrics and Evaluation: GBD Profile: France. [http://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_france.pdf]
  25. Institute for Health Metrics and Evaluation: GBD Profile: Greece. [http://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_greece.pdf]
  26. Institute for Health Metrics and Evaluation: GBD Profile: Italy. [http://www.healthdata.org/sites/default/files/files/country_profiles/GBD/ihme_gbd_country_report_italy.pdf]
  27. Tourlouki E, Matalas AL, Bountziouka V, Tyrovolas S, Zeimbekis A, Gotsis E, Tsiligianni I, Protopapa I, Protopapas C, Metallinos G, Lionis C, Piscopo S, Polychronopoulos E, Panagiotakos DB: Are current dietary habits in Mediterranean islands a reflection of the past? Results from the MEDIS study. Ecol Food Nutr. 2013, 52: 371-386. 10.1080/03670244.2012.707431.View ArticlePubMedGoogle Scholar
  28. Athanasiadis G, González-Pérez E, Esteban E, Dugoujon JM, Stoneking M, Moral P: The Mediterranean Sea as a barrier to gene flow: evidence from variation in and around the F7 and F12 genomic regions. BMC Evol Biol. 2010, 10: 84-10.1186/1471-2148-10-84.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Spanish Ministry of Health, Social Policy and Equality: Ischaemic heart disease strategy of the Spanish National Health System. Madrid: Spanish Ministry of Health, Social Policy and Equality; 2009. [ http://www.msc.es/organizacion/sns/planCalidadSNS/docs/Summary_Ischaemic_Heart_Disease_Strategy_Spanish_National_Health_System.pdf].
  30. Spanish Ministry of Health, Social Policy and Equality: Mental health strategy of the Spanish National Health System. Madrid: Spanish Ministry of Health, Social Policy and Equality; 2011. [http://www.msps.es/organizacion/sns/planCalidadSNS/docs/saludmental/SaludMental2009-2013.pdf]
  31. Hoy D, March L, Brooks P, Blyth F, Woolf A, Bain C, Williams G, Smith E, Vos T, Barendregt J, Murray C, Burstein R, Buchbinder R: The global burden of low back pain: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014, 73: 968-974. 10.1136/annrheumdis-2013-204428.View ArticlePubMedGoogle Scholar
  32. Hopman WM, Harrison MB, Coo H, Friedberg E, Buchanan M, VanDenKerkhof EG: Associations between chronic disease, age and physical and mental health status. Chronic Dis Can. 2009, 29: 108-116.PubMedGoogle Scholar
  33. Starfield B, Shi L, Macinko J: Contribution of primary care to health systems and health. Milbank Q. 2005, 83: 457-502. 10.1111/j.1468-0009.2005.00409.x.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas I, Stefanadis C: Prevalence and five-year incidence (2001–2006) of cardiovascular disease risk factors in a Greek sample: the ATTICA study. Hellenic J Cardiol. 2009, 250: 388-395.Google Scholar
  35. World Health Organization: Active Ageing: A Policy Framework. Geneva: WHO; 2002. [http://whqlibdoc.who.int/hq/2002/WHO_NMH_NPH_02.8.pdf]
  36. World Health Organization: Global Strategy on Diet, Physical Activity and Health. 2004, WHO, GenevaGoogle Scholar
  37. World Health Organization: Strengthening Public Health Services Across the European Region – A Summary of Background Documents for the European Action Plan. Denmark: WHO Regional Office for Europe; 2012. [http://www.euro.who.int/__data/assets/pdf_file/0017/172016/RC62-id05-final-Eng.pdf]

Copyright

© Haro et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement